[go: up one dir, main page]

CN105384825A - 一种基于单域抗体的双特异性嵌合抗原受体及其应用 - Google Patents

一种基于单域抗体的双特异性嵌合抗原受体及其应用 Download PDF

Info

Publication number
CN105384825A
CN105384825A CN201510733585.2A CN201510733585A CN105384825A CN 105384825 A CN105384825 A CN 105384825A CN 201510733585 A CN201510733585 A CN 201510733585A CN 105384825 A CN105384825 A CN 105384825A
Authority
CN
China
Prior art keywords
single domain
seqidno
domain antibody
chimeric antigen
antigen receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201510733585.2A
Other languages
English (en)
Other versions
CN105384825B (zh
Inventor
范晓虎
周传初
庄秋传
王平艳
王林
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nanjing Legend Biotechnology Co Ltd
Original Assignee
Nanjing Legend Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nanjing Legend Biotechnology Co Ltd filed Critical Nanjing Legend Biotechnology Co Ltd
Priority to CN201510733585.2A priority Critical patent/CN105384825B/zh
Publication of CN105384825A publication Critical patent/CN105384825A/zh
Priority to PH1/2018/500295A priority patent/PH12018500295B1/en
Priority to PT221681612T priority patent/PT4063397T/pt
Priority to CA2994579A priority patent/CA2994579C/en
Priority to DK22168161.2T priority patent/DK4063397T3/da
Priority to US15/751,609 priority patent/US10934363B2/en
Priority to UAA201802367A priority patent/UA125818C2/uk
Priority to RS20240831A priority patent/RS65866B1/sr
Priority to MX2018001739A priority patent/MX2018001739A/es
Priority to KR1020247039135A priority patent/KR20240173368A/ko
Priority to CR20210225A priority patent/CR20210225A/es
Priority to MYPI2018000199A priority patent/MY188362A/en
Priority to BR112018002844-4A priority patent/BR112018002844A2/pt
Priority to EP24174651.0A priority patent/EP4424376A3/en
Priority to NZ758571A priority patent/NZ758571A/en
Priority to EP22168161.2A priority patent/EP4063397B1/en
Priority to PL22168161.2T priority patent/PL4063397T3/pl
Priority to IL294683A priority patent/IL294683A/en
Priority to AU2016305075A priority patent/AU2016305075B2/en
Priority to LTEP22168161.2T priority patent/LT4063397T/lt
Priority to SM20240311T priority patent/SMT202400311T1/it
Priority to NZ778787A priority patent/NZ778787B2/en
Priority to IL257297A priority patent/IL257297B/en
Priority to CR20180153A priority patent/CR20180153A/es
Priority to HUE22168161A priority patent/HUE067869T2/hu
Priority to FIEP22168161.2T priority patent/FI4063397T3/fi
Priority to JP2018526984A priority patent/JP6859347B2/ja
Priority to KR1020187006996A priority patent/KR20180035918A/ko
Priority to EP16834662.5A priority patent/EP3334765A4/en
Priority to SI201631840T priority patent/SI4063397T1/sl
Priority to SG10201913485QA priority patent/SG10201913485QA/en
Priority to ES22168161T priority patent/ES2984851T3/es
Priority to EA201890302A priority patent/EA201890302A1/ru
Priority to PCT/CN2016/094408 priority patent/WO2017025038A1/en
Priority to ZA2018/00703A priority patent/ZA201800703B/en
Priority to CL2018000378A priority patent/CL2018000378A1/es
Priority to MX2022015823A priority patent/MX2022015823A/es
Priority to SA518390904A priority patent/SA518390904B1/ar
Priority to CONC2018/0001405A priority patent/CO2018001405A2/es
Application granted granted Critical
Publication of CN105384825B publication Critical patent/CN105384825B/zh
Priority to AU2020200151A priority patent/AU2020200151C1/en
Priority to US17/164,125 priority patent/US20210261675A1/en
Priority to JP2021052453A priority patent/JP7168173B2/ja
Priority to CL2021001686A priority patent/CL2021001686A1/es
Priority to AU2022204180A priority patent/AU2022204180A1/en
Priority to JP2022167222A priority patent/JP2022183283A/ja
Priority to JP2024014929A priority patent/JP2024032975A/ja
Priority to NL301301C priority patent/NL301301I2/nl
Priority to LTPA2024535C priority patent/LTPA2024535I1/lt
Priority to FR24C1050C priority patent/FR24C1050I2/fr
Priority to FIC20240042C priority patent/FIC20240042I1/fi
Priority to JP2025134318A priority patent/JP2025159117A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001116—Receptors for cytokines
    • A61K39/001117—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR] or CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4214—Receptors for cytokines
    • A61K40/4215—Receptors for tumor necrosis factors [TNF], e.g. lymphotoxin receptor [LTR], CD30
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4221—CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4222—CD38 not IgG
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5156—Animal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/29—Multispecific CARs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

本发明公开了一种基于单域抗体的双特异性嵌合抗原受体及其应用。所述的双特异性单域抗体嵌合抗原受体由CD8信号肽、CD19及CD20抗原特异性的两个单域抗体和CD28跨膜区以及CD28、CD3胞内信号传导结构域依次串联组成。本发明通过优化设计CD19、CD20特异的单域抗体，提供了一种CD19、CD20双靶点修饰的CAR‐T细胞，能够特异地与CD19及CD20抗原结合。在B淋巴细胞系恶性肿瘤杀伤试验中，采用CD19、CD20双靶点修饰的CAR‐T细胞进行CAR‐T疗法与单独的CD19或CD20CAR‐T相比，明显加强了免疫细胞靶向识别肿瘤细胞的能力，也增强了对肿瘤细胞的杀伤活性。

Description

一种基于单域抗体的双特异性嵌合抗原受体及其应用
技术领域
本发明属于生物医学或生物制药技术领域，涉及一种基于单域抗体的双特异性嵌合抗原受体及其应用。
背景技术
随着肿瘤免疫学理论和临床技术的发展，嵌合抗原受体T细胞疗法(ChimericantigenreceptorT-cellimmunotherapy，CAR-T)成为目前最有发展前景的肿瘤免疫疗法之一。一般，嵌合抗原受体CAR由一个肿瘤相关抗原结合区、胞外铰链区、跨膜区域以及胞内信号转导区组成。CAR-T细胞疗法通过外源基因转染技术，把识别肿瘤相关抗原的单链抗体(Singlechainfragmentvariable，scFv)和T细胞活化序列的融合蛋白表达到T细胞表面，使可以特异识别肿瘤相关抗原的scFv通过跨膜区与T细胞胞内的活化增殖信号域偶联。表达CAR的T细胞以抗原依赖、但非MHC限制的方式结合肿瘤抗原，启动并活化特异性杀伤肿瘤反应。
CD19、CD20分子是治疗B淋巴细胞系肿瘤潜在的靶点，也是CAR研究中的热点。靶向CD19分子的嵌合抗原受体基因修饰的T细胞(CD19CAR-T)在治疗多发性、难治性的急性B淋巴细胞白血病上取得巨大成功，而在难治性、复发性慢性B淋巴细胞白血病和B淋巴细胞系淋巴瘤的治疗中疗效明显较差。CD20分子也是B淋巴细胞系淋巴瘤，尤其是慢性、套细胞淋巴瘤表面的靶标分子。一般在CD19阳性的B细胞表面都会表达CD20。所以理论上如果能实现针对CD19和CD20的双靶标的双特异性CAR-T技术，其对B淋巴细胞白血病和B淋巴细胞系淋巴瘤的疗效应该可以明显改善。
另外，目前针对CD19的CAR-T细胞疗法在治疗急性B淋巴细胞白血病的临床试验中虽然可以在短期内实现90％左右的完全缓解疗效，但在治疗后数月后发现有约10％的患者发生远期复发，主要原因是残存肿瘤细胞产生了CD19缺失的变异株。因而同时设计针对肿瘤表面CD19及CD20抗原进行协同CAR-T疗法，将不仅有效提高T细胞加强杀伤信号并且可以利用像抗生素联用一样的原理，有效地避免发生靶点逃逸现象引起的远期白血病复发。
CAR-T细胞的有效激活均严重依赖识别肿瘤相关抗原的抗体的特异性以及抗原结合的亲和力高低等性质。所以在目前CAR-T细胞胞内信号转导区的设计已经趋于成熟的现状下，抗原结合区的设计成为新型CAR-T技术开发的重点和关键。从骆驼源重链抗体(Heavychainantibody,HCAb)中克隆出仅由一个重链可变区组成的单链抗体，其大小仅为2.4×4nm，是能够结合抗原的最小片段，称为单域抗体(Variabledomainofheavychainofheavy-chainantibody,VHH)或纳米抗体。与传统抗体相比，VHH单域抗体分子量小且表达量高，化学稳定性好，亲和力高并且与人源抗体同源性高，免疫原性低。分子量小易于进行基因工程改造，构建双重或多重特异性的单域抗体组合，达到一个分子多靶点或多种功能的效果。VHH组织渗透性好，在进行肿瘤治疗时，具有接触到不能被常规抗体接触的较为隐蔽的靶点的可能性。正由于这些优点，利用单域抗体作为CAR的抗原结合区进行CAR修饰及CAR-T细胞疗法是CAR疗法的创新性的发展。
发明内容
本发明的目的是针对现有技术的上述不足，提供一种应用于高效拮抗包括血液病在内的各种癌症的多靶点的CAR-T细胞疗法中的双特异性单域抗体嵌合抗原受体。
本发明的另一目的是提供含有该双特异性单域抗体嵌合抗原受体的T淋巴细胞或其他免疫效应细胞。
本发明的又一目的是提供该双特异性单域抗体嵌合抗原受体的应用。
本发明的目的可通过以下技术方案实现：一种基于单域抗体的双特异性嵌合抗原受体，胞外信号肽，由两个不同单域抗体构成的抗原结合结构域，跨膜结构域和胞内信号传导结构域共同组成。
所述基于单域抗体的双特异性嵌合抗原受体,其抗原与恶性肿瘤相关联，可以选自CD19、CD20、CD22、CD33/IL3Rα、CD38、BCMA、CS1、CD138、c-Met、EGFRvIII、GD-2、NY-ESO-1、MAGEA3、糖脂F77中任意二者的组合；优选CD19与CD20的组合；进一步优选的包括CD19及CD20抗原特异性的两个单域抗体VHH链组成的抗原结合结构域，并由一个Linker连接。
其中，所述的CD19抗原特异性的单域抗体VHH链包括框架区FR和互补决定区CDR，所述框架区FR包括FR1～FR4的氨基酸序列：SEQIDNO:4所示的FR1，SEQIDNO:5所示的FR2，SEQIDNO:6所示的FR3，SEQIDNO:7所示的FR4；所述互补决定区CDR包括CDR1～CDR3的氨基酸序列：SEQIDNO:8所示的CDR1，SEQIDNO:9所示的CDR2，SEQIDNO:10所示的CDR3。
所述的CD19抗原特异性的单域抗体VHH链优选具有SEQIDNO:3所示的氨基酸序列。
编码所述的CD19抗原特异性的单域抗体VHH链的核苷酸序列优选如SEQIDNO:11所示。
所述的CD20抗原特异性的单域抗体VHH链包括框架区FR和互补决定区CDR，所述框架区FR包括FR1～FR4的氨基酸序列：SEQIDNO:13所示的FR1，SEQIDNO:14所示的FR2，SEQIDNO:15所示的FR3，SEQIDNO:16所示的FR4；所述互补决定区CDR包括CDR1～CDR3的氨基酸序列：SEQIDNO:17所示的CDR1，SEQIDNO:18所示的CDR2，SEQIDNO:19所示的CDR3。
所述的CD20抗原特异性的单域抗体VHH链优选具有SEQIDNO:12所示的氨基酸序列。
编码所述的CD20抗原特异性的单域抗体VHH链的核苷酸序列如SEQIDNO:20所示。
所述基于单域抗体的双特异性嵌合抗原受体优选进一步包括共刺激信号传导区，包括选自下列的共刺激分子的细胞内结构域：CD27、CD28、4-1BB、OX40、CD30、CD40、CD3、淋巴细胞功能相关抗原-1(LFA-1)、CD2、CD7、LIGHT、NKG2C、B7-H3与CD83特异性结合的配体和其任意组合。
所述基于单域抗体的双特异性嵌合抗原受体优选地由CD8信号肽、CD19及CD20抗原特异性的两个单域抗体、CD28跨膜区以及CD28、CD3胞内信号传导结构域依次串联组成。
所述基于单域抗体的双特异性嵌合抗原受体更进一步优选具有SEQIDNO:1所示的氨基酸序列，其编码基因序列如SEQIDNO:2所示。
一种基因工程改造的免疫效应细胞，包括编码本发明所述的双特异性嵌合抗原受体的核苷酸序列。所述的免疫效应细胞选自T淋巴细胞、NK细胞，造血干细胞、多能干细胞或胚胎干细胞培养分化的免疫细胞，优选T淋巴细胞。
其中，所述嵌合抗原受体优选由CD8信号肽、CD19及CD20抗原特异性的两个单域抗体、CD28跨膜区以及CD28、CD3胞内信号传导结构域依次串联组成。
所述嵌合抗原受体进一步优选具有SEQIDNO:1所示的氨基酸序列，其编码基因序列如SEQIDNO:2所示。
本发明所述的双特异性嵌合抗原受体在制备抗肿瘤药物中的应用；优选在制备抗血液恶性肿瘤的药物中的应用。
本发明所述的免疫效应细胞在制备抗肿瘤药物中的应用；优选在制备抗血液恶性肿瘤的药物中的应用。
有益效果：
我们利用基因工程手段设计双特异性单域抗体作为CAR的抗原结合区进行CAR修饰及CAR-T细胞疗法是CAR疗法的创新性的发展。例如，将两个单域抗体结合起来(两个重链串联)蛋白质结构上和一个重链与轻链串联的scFv其实非常相似，我们的研究也证实双特异性单域抗体完全可以作为CAR技术的抗原结合域使用，从而成功地实现了双靶点双特异性的CAR技术，也在疗效试验中验证了前述双特异性CAR技术相对于传统CAR-T技术的多种理论优势。同时我们发现此发明还得以避免了以scFv为基础设计的CAR-T所常有的表达困难、稳定性差等缺陷。我们的CD19xCD20双特异性单域抗体-CAR技术在体外高效地转导了健康人T淋巴细胞，对于CD19和CD20阳性的靶细胞产生了强力的杀伤效果，在基于NOG小鼠的高质量人淋巴瘤模式动物体内起到了比单特异性CAR-T更好的治疗效果。
本发明通过优化设计CD19、CD20特异的单域抗体，提供了一种CD19、CD20双靶点修饰的CAR-T细胞，能够特异地与CD19及CD20抗原结合。此外，在B淋巴细胞系恶性肿瘤治疗中，采用CD19、CD20双靶点修饰的CAR-T细胞进行CAR-T疗法与单独的CD19或CD20CAR-T相比，明显增强了免疫细胞靶向识别肿瘤抗原的能力，加强了对肿瘤细胞的杀伤活性。
附图说明
图1为基于CD19xCD20单域抗体的嵌合抗原受体结构图。
图2为基于CD19xCD20单域抗体双特异性CAR-T体外杀伤效果图。其中，Raji细胞为靶细胞，A)只加入未转导的T细胞，B)加入CD19CAR-T细胞，C)加入CD19CAR-T细胞，D)加入CD19xCD20CAR-T细胞。根据Raji细胞占总细胞的比例结果显示，与未加入CAR-T细胞的对照组相比，B)、C)与D)组对Raji肿瘤细胞均有杀伤作用，而CD19xCD20CAR-T细胞的杀伤效果最好。
图3为小鼠生存曲线；分别对24只NOG小鼠尾静脉注射Raji细胞。10天以后，将注射Raji细胞的小鼠随机分成四组，分别注射等量(400万细胞)的T细胞、CD19CAR-T细胞、CD20CAR-T细胞以及CD19xCD20CAR-T细胞。连续观察动物5周，记录小鼠死亡时间。注射未转导T细胞的小鼠基本上在20天内全部死亡，注射CD19CAR-T细胞的小鼠在40天时发生1例死亡，注射CD20CAR-T细胞的小鼠在42天时发生1例死亡，而注射CD19xCD20CAR-T细胞的小鼠在观察期间均未发生死亡。
具体实施方式
本发明利用多个各自特异的单域抗体进行CAR设计修饰，涉及识别多个靶点的CAR-T技术，协同杀伤包括血液系肿瘤的肿瘤，防止免疫逃逸及肿瘤复发。下面结合具体实施例，进一步阐述本发明。
实施例1CD19与CD20单域抗体制备
(一)CD19与CD20单域抗体文库构建
利用购自R&DSYSTEMS公司的CD19及CD20抗原对美洲驼进行定期免疫。第一次免疫时，分别将200μg重组CD19或CD20蛋白与等体积弗氏佐剂混合，其后用弗氏不完全佐剂与抗原混合，进行免疫，每周一次。经多次免疫加强美洲驼对靶抗原的免疫应激反应，刺激B细胞表达针对靶抗原的重链抗体。
免疫期间对免疫动物取血采样，评估免疫反应效果。免疫结束后，取100mL美洲驼外周血淋巴细胞并提取TotalRNA，并反转录成cDNA，通过二次PCR扩增美洲驼重链抗体的可变区片段VHH。将VHH片段构建入噬菌体展示载体中，并通过电转化将携带有单域抗体基因片段的产物转入感受态大肠杆菌中，从而获得单域抗体免疫文库。
第一次PCR模板：cDNA；
上游引物CALL001，如SEQIDNO:21所示：5’-GTCCTGGCTGCTCTTCTACAAGG-3’；
下游引物CALLOO2，如SEQIDNO:22所示：5’-GGTACGTGCTGTTGAACTGTTCC-3’；
第二次PCR模板：第一次PCR割胶回收产物；
上游引物BACK-1，如SEQIDNO:23所示：5’-GATGTGCAGCTGCAGGAGTCTGGAGGAGG-3’；BACK-2，如SEQIDNO:24所示：5’-GATGTGCAGCTGCAGGAGTCTGGGGGAGG-3’；
下游引物PMCF，如SEQIDNO:25所示：5’-CTAGTGCGGCCGCTGAGGAGACGGTGACCTGGGT-3’；
两次PCR程序均为：预变性94℃、7min，变性94℃、1min，退火55℃、1min，延伸72℃、7min。
(二)CD19与CD20单域抗体筛选及表达
利用噬菌体展示技术将单域抗体分子展示于噬菌体表面，进而筛选出抗原特异性的单域抗体。通过噬菌体酶联免疫吸附ELISA方法，将抗原用100mMNaHCO3(pH8.0)稀释至终浓度为100μg/mL,包被100μL至96孔板中，4℃过夜。经过PBS冲洗、1％脱脂牛奶封闭后，加入噬菌体孵育1～2h，然后将抗原特异性的噬菌体洗脱并侵染TG1细胞，在含有氨苄青霉素的LB培养板上涂布培养，经过多轮筛选逐步达到富集。挑选大量阳性克隆进行ELISA检测并对阳性克隆进行测序，根据序列比对，确定独特的的克隆并将其序列分为框架区FR和互补决定区CDR。
将测序正确的克隆接种在5mL含有氨苄青霉素的LB培养液中，37℃摇床培养过夜；接种1mL的菌液至300mLTB培养液中，37℃摇床培养至OD600nm＝0.6～0.9时，加入1MIPTG，28℃摇床培养过夜；离心，收菌；利用渗透法，获得抗体粗提液；通过ProteinL标记并利用亲和层析法纯化出单域抗体，其产量均在10mg/L以上。利用SPR技术检测抗体的亲和力，进一步筛选出特异性高的单域抗体。通过以上实施方式，共获得6株CD19单域抗体、5株CD20单域抗体。选择亲和力较高的单域抗体，其中一株CD19单域抗体具有SEQIDNO:11所示的核甘酸序列，一株CD20单域抗体具有SEQIDNO:20所示的核甘酸序列。
实施例2CD19与CD20双特异性嵌合抗原受体修饰的T细胞的制备
(一)嵌合抗原受体基因片段制备
本发明按以下编码基因的顺序设计融合基因片段：CD8信号肽、CD19VHH-linker-CD20VHH、CD28跨膜区以及CD28和CD3ζ胞内信号结构域，通过基因合成技术直接合成该融合基因，使表达的嵌合抗原受体具有CD8α-VHH(CD19-linker-CD20)-CD28TM-CD28-CD3ζ的氨基酸结构。将购自Clontech公司的pLVX-Puro载体的CMV启动子改造为人EF1a启动子从而获得pLVX-hEF1α载体，将合成的基因片段构建在pLVX-hEF1α载体上，形成重组质粒，命名为pLVX-CD8α-VHH(CD19-linker-CD20)-CD28TM-CD28-CD3ζ。
CD8信号肽的核酸序列如SEQIDNO:26所示；
Linker的核酸序列如SEQIDNO:27所示；
CD28TM及CD28-CD3ζ胞内信号结构域的核酸序列如SEQIDNO:28所示；
(二)嵌合抗原受体慢病毒表达载体的构建
在本发明中，CAR-T细胞通过基因修饰的CAR、慢病毒表达载体构建，转导T细胞而获得。提取pLVX-CD8α-VHH(CD19-linker-CD20)-CD28TM-CD28-CD3ζ表达质粒和pRRE、pRSV-rev及pMD2.G辅助质粒，按一定比例混合，共转染293T细胞。转染48h、96h后，收集含有病毒的细胞培养上清，4℃、3000rpm离心5min。上清经0.45μm滤器过滤后，与PEG8000/NaCl按4:1体积混匀，4℃静置2～3h后高速离心30min。弃上清，沉淀用预冷的PBS重悬溶解，即获得病毒浓缩液，-80℃保存备用。
(三)T淋巴细胞的制备
取50mL健康人新鲜血液，通过淋巴细胞分离液、密度梯度离心方法分离外周血单核细胞(PBMC)。利用PanTCellIsolationKit(购自MiltenyiBiotech)对细胞进行磁珠标记，并分离纯化出T淋巴细胞。纯化后的T细胞，再利用CD3/CD28磁珠进行T淋巴细胞激活及增殖。
(四)慢病毒转导T淋巴细胞
收集激活的T淋巴细胞，重悬在含有终浓度为100IU/mLIL-2的R10培养基中。用相同培养基将慢病毒稀释至MOI＝5，感染1x106个活化的T淋巴细胞，并加入终浓度为7μg/mL的聚凝胺，32℃、1000g离心1h。将细胞悬液加在24孔板中，置37℃、5％CO2培养箱中孵育过夜。第二天，再次离心并换新鲜培养基，每隔2天检测一次细胞浓度。当细胞浓度达到2x106个/mL时，离心吸取1mL细胞悬液到另一个孔中，并分别加入新鲜培养基，继续扩大培养。
实施例3CD19与CD20双特异性CAR-T细胞对肿瘤的杀伤试验
(一)体外杀伤试验
离心收集实施例2中制备的CD19xCD20CAR-T细胞，用含10％人AB血清的DPBS调节浓度，洗涤三次后接种在96孔板中，用ProteinL进行标记。Raji肿瘤细胞用Calcein-AM标记，标记后的CAR-T与肿瘤细胞按1:1、5:1、10:1及20:1比率在37℃条件下共培养4h，利用流式细胞技术FACS进行检测。每种细胞设置三个阴性对照，分别为只加CD19CAR-T或CD20CAR-T及非CAR修饰的T细胞的肿瘤细胞。试验结果显示与未注射CAR-T细胞的对照组相比，B)、C)与D)组对Raji肿瘤细胞均有杀伤作用，而CD19xCD20CAR-T细胞的杀伤效果最好。
(二)动物模型试验
扩增Raji细胞，按4x106细胞量/只小鼠，分别进行24只高度免疫缺陷NOG小鼠尾静脉注射，建立模型。10天后将注射Raji细胞的小鼠分成四组，每组6只，分别注射等量的Tcell、CD19CAR-Tcell、CD20CAR-Tcell、CD19xCD20CAR-Tcell。连续饲养5周，观察小鼠状态，若有小鼠死亡，及时记录死亡时间，绘制小鼠生存曲线。小鼠模型试验表明，注射T细胞的小鼠基本上在20天内死亡，注射单一CD19CAR-Tcell或CD20CAR-Tcell的小鼠有少量死亡，而注射CD19xCD20CAR-T细胞的小鼠均未发生死亡，说明本发明设计的CD19xCD20CAR-T细胞在模式动物体内同样对肿瘤细胞具有杀伤作用。

Claims (16)

1.一种基于单域抗体的双特异性嵌合抗原受体，其特征在于包括胞外信号肽，由两个不同单域抗体构成的抗原结合结构域，跨膜结构域和胞内信号传导结构域。
2.根据权利要求1所述基于单域抗体的双特异性嵌合抗原受体，其特征在于所述抗原与恶性肿瘤相关联，选自CD19、CD20、CD22、CD33/IL3Rα、CD38、BCMA、CS1、CD138、c‐Met、EGFRvIII、GD‐2、NY‐ESO‐1、MAGEA3、糖脂F77或其他肿瘤表面抗原中任意两种的组合；优选地包括CD19及CD20抗原特异性的两个单域抗体VHH链组成的抗原结合结构域，并由一个Linker连接。
3.根据权利要求2所述基于单域抗体的双特异性嵌合抗原受体，其特征在于所述的CD19抗原特异性的单域抗体VHH链包括框架区FR和互补决定区CDR，所述框架区FR包括FR1～FR4的氨基酸序列：SEQIDNO:4所示的FR1，SEQIDNO:5所示的FR2，SEQIDNO:6所示的FR3，SEQIDNO:7所示的FR4；所述互补决定区CDR包括CDR1～CDR3的氨基酸序列：分别具有与SEQIDNO:8所示的CDR1，SEQIDNO:9所示的CDR2，SEQIDNO:10所示的CDR3序列85％以上同一性的氨基酸序列。
4.根据权利要求3所述基于单域抗体的双特异性嵌合抗原受体，其特征在于所述的CD19抗原特异性的单域抗体VHH链具有SEQIDNO:3所示序列85％以上同一性的氨基酸序列。
5.根据权利要求4所述基于单域抗体的双特异性嵌合抗原受体，其特征在于编码所述的CD19抗原特异性的单域抗体VHH链的核苷酸序列如SEQIDNO:11所示。
6.根据权利要求2所述基于单域抗体的双特异性嵌合抗原受体，其特征在于所述的CD20抗原特异性的单域抗体VHH链包括框架区FR和互补决定区CDR，所述框架区FR包括FR1～FR4的氨基酸序列：SEQIDNO:13所示的FR1，SEQIDNO:14所示的FR2，SEQIDNO:15所示的FR3，SEQIDNO:16所示的FR4；所述互补决定区CDR包括CDR1～CDR3的氨基酸序列：分别具有与SEQIDNO:17所示的CDR1，SEQIDNO:18所示的CDR2，SEQIDNO:19所示的CDR3序列85％以上同一性的氨基酸序列。
7.根据权利要求6所述基于单域抗体的双特异性嵌合抗原受体，其特征在于所述的CD20抗原特异性的单域抗体VHH链具有SEQIDNO:12所示序列85％以上同一性的氨基酸序列。
8.根据权利要求7所述基于单域抗体的双特异性嵌合抗原受体，其特征在于编码所述的CD20抗原特异性的单域抗体VHH链的核苷酸序列如SEQIDNO:20所示。
9.根据权利要求2所述基于单域抗体的双特异性嵌合抗原受体，其特征在于所述嵌合抗原受体进一步包括共刺激信号传导区，包括选自下列的共刺激分子的细胞内信号传导结构域：CD27、CD28、4‐1BB、OX40、CD30、CD40、CD3、淋巴细胞功能相关抗原‐1(LFA‐1)、CD2、CD7、LIGHT、NKG2C、B7‐H3与CD83特异性结合的配体和其任意组合。
10.根据权利要求1～9中任一项所述基于单域抗体的双特异性嵌合抗原受体，其特征在于所述嵌合抗原受体由CD8信号肽、CD19及CD20抗原特异性的两个单域抗体、CD28跨膜区以及CD28、CD3胞内信号传导结构域依次串联组成。
11.根据权利要求10所述基于单域抗体的双特异性嵌合抗原受体，其特征在于所述嵌合抗原受体具有SEQIDNO:1所示的氨基酸序列，其编码基因序列如SEQIDNO:2所示。
12.一种基因工程改造的免疫效应细胞，其特征在于包括编码权利要求1～9中任一项所述的双特异性嵌合抗原受体的核苷酸序列；所述的免疫效应细胞选自T淋巴细胞、NK细胞，造血干细胞、多能干细胞或胚胎干细胞培养分化的免疫细胞,优选T淋巴细胞。
13.根据权利要求12所述的基因工程改造的免疫效应细胞，其特征在于所述嵌合抗原受体由CD8信号肽、CD19及CD20抗原特异性的两个单域抗体、CD28跨膜区以及CD28、CD3胞内信号传导结构域依次串联组成。
14.根据权利要求13所述的基因工程改造的免疫效应细胞，其特征在于所述嵌合抗原受体具有SEQIDNO:1所示的氨基酸序列，其编码基因序列如SEQIDNO:2所示。
15.权利要求1～9中任一项所述基于单域抗体的双特异性嵌合抗原受体在制备抗肿瘤药物中的应用；优选在制备抗血液恶性肿瘤的药物中的应用。
16.权利要求12所述的免疫效应细胞在制备抗肿瘤药物中的应用；优选在制备抗恶性肿瘤的药物中的应用。
CN201510733585.2A 2015-08-11 2015-11-02 一种基于单域抗体的双特异性嵌合抗原受体及其应用 Active CN105384825B (zh)

Priority Applications (51)

Application Number Priority Date Filing Date Title
CN201510733585.2A CN105384825B (zh) 2015-08-11 2015-11-02 一种基于单域抗体的双特异性嵌合抗原受体及其应用
PH1/2018/500295A PH12018500295B1 (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PT221681612T PT4063397T (pt) 2015-08-11 2016-08-10 Recetores de antigénios quiméricos com base em anticorpos de domínio único e métodos de utilização dos mesmos
CA2994579A CA2994579C (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
DK22168161.2T DK4063397T3 (da) 2015-08-11 2016-08-10 Kimære antigenreceptorer baseret på enkelt-domæneantistoffer og fremgangsmåder til anvendelse deraf
US15/751,609 US10934363B2 (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single domain antibodies and methods of use thereof
UAA201802367A UA125818C2 (uk) 2015-08-11 2016-08-10 Химерні рецептори антигенів на основі однодоменних антитіл і способи їх застосування
RS20240831A RS65866B1 (sr) 2015-08-11 2016-08-10 Himerni antigen receptori bazirani na jednodomenskim antitelima i postupci njihove upotrebe
MX2018001739A MX2018001739A (es) 2015-08-11 2016-08-10 Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos.
KR1020247039135A KR20240173368A (ko) 2015-08-11 2016-08-10 단일-도메인 항체에 근거된 키메라 항원 수용체 및 이들의 이용 방법
CR20210225A CR20210225A (es) 2015-08-11 2016-08-10 RECEPTORES DE ANTÍGENES QUIMÉRICOS BASADOS EN ANTICUERPOS DE DOMINIO SIMPLE Y MÉTODOS DE USO DE ESTOS (Divisional 2018-0153)
MYPI2018000199A MY188362A (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
BR112018002844-4A BR112018002844A2 (pt) 2015-08-11 2016-08-10 receptores de antígeno quimérico à base de anticorpos de domínio único e métodos de uso dos mesmos
EP24174651.0A EP4424376A3 (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
NZ758571A NZ758571A (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
EP22168161.2A EP4063397B1 (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
PL22168161.2T PL4063397T3 (pl) 2015-08-11 2016-08-10 Chimeryczne receptory antygenowe oparte na przeciwciałach jednodomenowych i sposoby ich zastosowania
IL294683A IL294683A (en) 2015-08-11 2016-08-10 Chimeric Antigen Receptors Based on Single-Site Antibodies and Methods for Using Them
AU2016305075A AU2016305075B2 (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
LTEP22168161.2T LT4063397T (lt) 2015-08-11 2016-08-10 Chimeriniai antigeno receptoriai, sukonstruoti vieno domeno antikūnų pagrindu, ir jų panaudojimo būdai
SM20240311T SMT202400311T1 (it) 2015-08-11 2016-08-10 Recettori antigeni chimerici basati su anticorpi a dominio singolo e relativi metodi di utilizzo
NZ778787A NZ778787B2 (en) 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
IL257297A IL257297B (en) 2015-08-11 2016-08-10 Chimeric Antigen Receptors Based on Single-Site Antibodies and Methods for Using Them
CR20180153A CR20180153A (es) 2015-08-11 2016-08-10 Receptores de antígenes quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
HUE22168161A HUE067869T2 (hu) 2015-08-11 2016-08-10 Egydoménes antitesteken alapuló kiméra antigén-receptorok és eljárások alkalmazásukra
FIEP22168161.2T FI4063397T3 (fi) 2015-08-11 2016-08-10 Yksidomeenivasta-aineisiin perustuvia antigeenireseptoreita ja menetelmiä niiden käyttämiseksi
JP2018526984A JP6859347B2 (ja) 2015-08-11 2016-08-10 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
KR1020187006996A KR20180035918A (ko) 2015-08-11 2016-08-10 단일-도메인 항체에 근거된 키메라 항원 수용체 및 이들의 이용 방법
EP16834662.5A EP3334765A4 (en) 2015-08-11 2016-08-10 CHIMERIC ANTIGEN RECEPTORS BASED ON INDIVIDUAL DOMAIN ANTIBODIES AND METHOD FOR USE THEREOF
SI201631840T SI4063397T1 (sl) 2015-08-11 2016-08-10 Himerni antigenski receptorji na osnovi enodomenskih protiteles in načini za njihovo uporabo
SG10201913485QA SG10201913485QA (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
ES22168161T ES2984851T3 (es) 2015-08-11 2016-08-10 Receptores de antígeno quiméricos basados en anticuerpos de dominio único y métodos de uso de los mismos
EA201890302A EA201890302A1 (ru) 2015-08-11 2016-08-10 Химерные рецепторы антигенов на основе однодоменных антител и способы их применения
PCT/CN2016/094408 WO2017025038A1 (en) 2015-08-11 2016-08-10 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
ZA2018/00703A ZA201800703B (en) 2015-08-11 2018-02-02 Chimeric antigen receptors based on single¿domain antibodies and methods of use thereof
CL2018000378A CL2018000378A1 (es) 2015-08-11 2018-02-09 Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos
MX2022015823A MX2022015823A (es) 2015-08-11 2018-02-09 Receptores de antigenos quimerlcos basados en anticuerpos de dominio simple y metodos de uso de estos.
SA518390904A SA518390904B1 (ar) 2015-08-11 2018-02-11 مستقبلات مولد مضاد خيمرية تقوم على أجسام مضادة أحادية الحقل وطرق لاستخدامها
CONC2018/0001405A CO2018001405A2 (es) 2015-08-11 2018-02-13 Receptores de antígenos quiméricos basados en anticuerpos de dominio simple
AU2020200151A AU2020200151C1 (en) 2015-08-11 2020-01-08 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
US17/164,125 US20210261675A1 (en) 2015-08-11 2021-02-01 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
JP2021052453A JP7168173B2 (ja) 2015-08-11 2021-03-25 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
CL2021001686A CL2021001686A1 (es) 2015-08-11 2021-06-23 Receptores de antígenos quiméricos basados en anticuerpos de dominio simple y métodos de uso de estos (divisional de solicitud n° 201800378)
AU2022204180A AU2022204180A1 (en) 2015-08-11 2022-06-15 Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
JP2022167222A JP2022183283A (ja) 2015-08-11 2022-10-18 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
JP2024014929A JP2024032975A (ja) 2015-08-11 2024-02-02 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法
NL301301C NL301301I2 (nl) 2015-08-11 2024-12-05 ciltacabtagene autoleucel
LTPA2024535C LTPA2024535I1 (zh) 2015-08-11 2024-12-09
FR24C1050C FR24C1050I2 (fr) 2015-08-11 2024-12-10 Récepteurs d'antigènes chimériques basés sur des anticorps à domaine unique et leurs méthodes d'utilisation
FIC20240042C FIC20240042I1 (fi) 2015-08-11 2024-12-11 siltakabtageeniautoleuseeli
JP2025134318A JP2025159117A (ja) 2015-08-11 2025-08-12 単一ドメイン抗体に基づくキメラ抗原受容体及びその使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2015104900028 2015-08-11
CN201510490002 2015-08-11
CN201510733585.2A CN105384825B (zh) 2015-08-11 2015-11-02 一种基于单域抗体的双特异性嵌合抗原受体及其应用

Publications (2)

Publication Number Publication Date
CN105384825A true CN105384825A (zh) 2016-03-09
CN105384825B CN105384825B (zh) 2018-06-01

Family

ID=55417644

Family Applications (9)

Application Number Title Priority Date Filing Date
CN201510733585.2A Active CN105384825B (zh) 2015-08-11 2015-11-02 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN201680047777.0A Pending CN109311999A (zh) 2015-08-11 2016-08-10 基于单结构域抗体的嵌合抗原受体及其使用方法
CN202110530320.8A Active CN113234173B (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN201780031233.XA Active CN109153731B (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202110529747.6A Pending CN113185615A (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202410221549.7A Pending CN118085090A (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202410006229.XA Pending CN117756941A (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202110529749.5A Active CN113185616B (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202110530335.4A Active CN113234174B (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法

Family Applications After (8)

Application Number Title Priority Date Filing Date
CN201680047777.0A Pending CN109311999A (zh) 2015-08-11 2016-08-10 基于单结构域抗体的嵌合抗原受体及其使用方法
CN202110530320.8A Active CN113234173B (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN201780031233.XA Active CN109153731B (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202110529747.6A Pending CN113185615A (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202410221549.7A Pending CN118085090A (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202410006229.XA Pending CN117756941A (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202110529749.5A Active CN113185616B (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法
CN202110530335.4A Active CN113234174B (zh) 2015-08-11 2017-08-10 靶向bcma的嵌合抗原受体及其使用方法

Country Status (36)

Country Link
US (6) US10934363B2 (zh)
EP (7) EP4424376A3 (zh)
JP (9) JP6859347B2 (zh)
KR (7) KR20240173368A (zh)
CN (9) CN105384825B (zh)
AU (5) AU2016305075B2 (zh)
BR (1) BR112018002844A2 (zh)
CA (3) CA2994579C (zh)
CL (4) CL2018000378A1 (zh)
CO (2) CO2018001405A2 (zh)
CR (4) CR20180153A (zh)
DK (2) DK4063397T3 (zh)
EA (2) EA201890302A1 (zh)
ES (2) ES2984851T3 (zh)
FI (3) FI4063397T3 (zh)
FR (1) FR24C1050I2 (zh)
HR (2) HRP20241057T1 (zh)
HU (3) HUE067869T2 (zh)
IL (3) IL257297B (zh)
LT (3) LT4063397T (zh)
MX (5) MX2018001739A (zh)
MY (3) MY188362A (zh)
NL (1) NL301301I2 (zh)
NO (1) NO2024054I1 (zh)
NZ (2) NZ791176A (zh)
PH (2) PH12018500295B1 (zh)
PL (2) PL4063397T3 (zh)
PT (2) PT4063397T (zh)
RS (2) RS65866B1 (zh)
SA (2) SA518390904B1 (zh)
SG (2) SG10201913485QA (zh)
SI (2) SI4063397T1 (zh)
SM (2) SMT202400311T1 (zh)
UA (2) UA125818C2 (zh)
WO (2) WO2017025038A1 (zh)
ZA (2) ZA201800703B (zh)

Cited By (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105647946A (zh) * 2016-03-18 2016-06-08 苏州康元生物科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
CN106701827A (zh) * 2016-12-05 2017-05-24 刘晓明 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法
CN106749677A (zh) * 2017-01-04 2017-05-31 上海交通大学医学院附属瑞金医院 一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
CN106755108A (zh) * 2016-12-05 2017-05-31 刘晓明 一种表达cd19和cd20抗体基因嵌合抗原受体的慢病毒载体及其制备方法
CN106755109A (zh) * 2016-12-05 2017-05-31 刘晓明 一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体
CN106822184A (zh) * 2016-12-15 2017-06-13 梁爱斌 多靶点联合的car‑t细胞制剂与制备方法
CN107245500A (zh) * 2017-05-27 2017-10-13 上海优卡迪生物医药科技有限公司 一种基于octs技术的淋系白血病car‑t治疗载体及其构建方法和应用
CN107299110A (zh) * 2017-05-27 2017-10-27 上海优卡迪生物医药科技有限公司 一种基于octs技术的胰腺癌、恶性间皮瘤car‑t治疗载体及其构建方法和应用
WO2017191476A1 (en) * 2016-05-06 2017-11-09 Crescendo Biologics Limited Chimeric antigen receptor with single domain antibody
WO2018028647A1 (en) * 2015-08-11 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
CN108220247A (zh) * 2018-03-20 2018-06-29 杭州史迪姆生物科技有限公司 一种双car-t细胞及其制备方法和应用
CN108276493A (zh) * 2016-12-30 2018-07-13 南京传奇生物科技有限公司 一种新型嵌合抗原受体及其应用
CN108285486A (zh) * 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
CN108314739A (zh) * 2018-02-05 2018-07-24 深圳市默赛尔生物医学科技发展有限公司 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN108341881A (zh) * 2018-01-31 2018-07-31 深圳市默赛尔生物医学科技发展有限公司 带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
KR20180133252A (ko) * 2016-04-01 2018-12-13 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
CN109134665A (zh) * 2018-08-24 2019-01-04 深圳普瑞金生物药业有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
CN109232742A (zh) * 2017-07-11 2019-01-18 深圳市第二人民医院 一种嵌合抗原受体及其应用
WO2019014891A1 (zh) * 2017-07-20 2019-01-24 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
CN109485732A (zh) * 2018-12-20 2019-03-19 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
CN109485734A (zh) * 2018-12-30 2019-03-19 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
CN109504660A (zh) * 2018-11-02 2019-03-22 温州启星生物技术有限公司 一种第四代car-t细胞及其构建方法和应用
CN109503716A (zh) * 2018-10-08 2019-03-22 生研医药科技（武汉）有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
CN109652379A (zh) * 2018-12-29 2019-04-19 博生吉医药科技(苏州)有限公司 Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途
EP3484927A1 (en) * 2016-07-15 2019-05-22 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
CN109843325A (zh) * 2016-09-14 2019-06-04 特尼奥生物股份有限公司 Cd3结合抗体
CN109843923A (zh) * 2016-10-11 2019-06-04 南京传奇生物科技有限公司 针对ctla-4的单结构域抗体及其变体
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
CN109988242A (zh) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 联合嵌合抗原受体、表达载体、慢病毒及t细胞
CN110129369A (zh) * 2018-02-09 2019-08-16 上海交通大学医学院附属上海儿童医学中心 一种嵌合抗原受体基因工程载体、免疫细胞及其应用
CN110372796A (zh) * 2018-04-12 2019-10-25 西比曼生物科技（香港）有限公司 靶向bcma的嵌合抗原受体及其制法和应用
CN110606893A (zh) * 2018-06-15 2019-12-24 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
JP2020505001A (ja) * 2016-12-21 2020-02-20 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
WO2020038147A1 (zh) * 2018-08-24 2020-02-27 深圳普瑞金生物药业有限公司 抗bcma的单域抗体及其应用
EP3485017A4 (en) * 2016-07-18 2020-03-04 Helix Biopharma Corp. IMMUNE CELLS CAR DIRECTED AGAINST CARCINO-EMBRYONARY ANTIGEN CELL ADHESION MOLECULE 6 FOR CANCER TREATMENT
CN110945026A (zh) * 2017-06-20 2020-03-31 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
WO2020061796A1 (en) * 2018-09-26 2020-04-02 Hrain Biotechnology Co., Ltd. Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof
CN111196858A (zh) * 2020-02-05 2020-05-26 武汉科技大学 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
WO2020108642A1 (en) * 2018-11-30 2020-06-04 Beijing Meikang Geno-Immune Biotechnology Co., Ltd. Cd19-and cd30-based combined car-t immunotherapy
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途
CN111574629A (zh) * 2020-06-01 2020-08-25 宁夏医科大学 一种抗cd20的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
CN111836827A (zh) * 2017-12-28 2020-10-27 南京传奇生物科技有限公司 包含nkg2d结构域的多特异性嵌合受体和其使用方法
US10975161B2 (en) 2016-01-12 2021-04-13 Crescendo Biologics Limited Molecules that bind prostate specific membrane antigen (PSMA)
CN112739721A (zh) * 2019-09-26 2021-04-30 苏州克睿基因生物科技有限公司 一种单域抗体及包含抗体结构的嵌合抗原受体
CN113330038A (zh) * 2019-01-22 2021-08-31 亘喜生物科技（上海）有限公司 Cd20组合靶向的工程化免疫细胞
CN114040927A (zh) * 2019-05-04 2022-02-11 印希比股份有限公司 结合cd33的多肽及其用途
CN114195898A (zh) * 2021-12-13 2022-03-18 南京凯地医疗技术有限公司 人源化抗cd33的单域抗体及其构建体制备方法和应用
EP3895712B1 (en) 2016-12-09 2022-06-22 ONK Therapeutics Limited Engineered natural killer cells and uses thereof
CN114685664A (zh) * 2022-04-12 2022-07-01 内蒙古农业大学 抗人b淋巴细胞表面抗原cd20的单域抗体及其应用
CN114829405A (zh) * 2019-12-10 2022-07-29 爱必乐生物公司 抗bcma/抗4-1bb双特异性抗体及其用途
US11401342B2 (en) 2017-07-10 2022-08-02 Crescendo Biologics Limited Therapeutic molecules binding PSMA
WO2022161409A1 (zh) * 2021-01-29 2022-08-04 武汉思安医疗技术有限公司 双特异性cs1-bcma car-t细胞及其应用
WO2022199590A1 (zh) * 2021-03-22 2022-09-29 浙江纳米抗体技术中心有限公司 一种靶向bcma的纳米抗体及其应用
US11505613B2 (en) 2016-04-01 2022-11-22 Kite Pharma, Inc. BCMA binding molecules and methods of use thereof
US11591398B2 (en) 2017-01-06 2023-02-28 Crescendo Biologics Limited Single domain antibodies to programmed cell death protein 1 (PD-1)
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
WO2023044991A1 (zh) * 2021-09-24 2023-03-30 四川大学 一种特异性靶向肿瘤EpCAM抗原的抗体及应用
CN116199781A (zh) * 2023-02-22 2023-06-02 成都优赛诺生物科技有限公司 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
CN116949099A (zh) * 2023-07-12 2023-10-27 山东大学第二医院 一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用
CN117024594A (zh) * 2023-09-21 2023-11-10 武汉波睿达生物科技有限公司 一种抗cd20的纳米抗体及其应用
CN117069844A (zh) * 2022-12-06 2023-11-17 成都赛恩吉诺生物科技有限公司 包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
US11905326B2 (en) 2019-06-14 2024-02-20 Teneobio, Inc. Multispecific heavy chain antibodies binding to CD22 and CD3
WO2024041650A1 (en) * 2022-08-25 2024-02-29 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2024051096A1 (zh) * 2022-09-05 2024-03-14 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
US11951172B2 (en) 2018-02-16 2024-04-09 Crescendo Biologics Limited Therapeutic molecules that bind to LAG3 and PD1
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
TWI841595B (zh) * 2018-09-10 2024-05-11 大陸商南京傳奇生物科技有限公司 針對ｃｄ３３之單域抗體及其構築體
US12005081B2 (en) 2019-04-30 2024-06-11 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
US12077595B2 (en) 2017-11-13 2024-09-03 Crescendo Biologics Limited Single domain antibodies that bind to CD137
WO2024240248A1 (zh) * 2023-05-24 2024-11-28 茂行制药(苏州)有限公司 用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
US12311022B2 (en) 2023-03-31 2025-05-27 AbelZeta Inc. Bispecific chimeric antigen receptors targeting CD20 and BCMA
CN120173114A (zh) * 2025-03-24 2025-06-20 广州泽朗生物医药科技有限公司 Cart细胞及其在制备抗癌症药物中的应用

Families Citing this family (333)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9950282B2 (en) 2012-03-15 2018-04-24 Flodesign Sonics, Inc. Electronic configuration and control for acoustic standing wave generation
US9458450B2 (en) 2012-03-15 2016-10-04 Flodesign Sonics, Inc. Acoustophoretic separation technology using multi-dimensional standing waves
US10704021B2 (en) 2012-03-15 2020-07-07 Flodesign Sonics, Inc. Acoustic perfusion devices
US10967298B2 (en) 2012-03-15 2021-04-06 Flodesign Sonics, Inc. Driver and control for variable impedence load
CA2935960C (en) 2014-01-08 2023-01-10 Bart Lipkens Acoustophoresis device with dual acoustophoretic chamber
EP4050103A1 (en) 2014-04-07 2022-08-31 Minerva Biotechnologies Corporation Anti-nme antibody
CN104004095B (zh) * 2014-06-04 2016-11-23 博生吉医药科技(苏州)有限公司 一种cd7纳米抗体、其编码序列及应用
US11253546B2 (en) 2014-12-15 2022-02-22 The Regents Of The University Of California Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20
US11021699B2 (en) 2015-04-29 2021-06-01 FioDesign Sonics, Inc. Separation using angled acoustic waves
US11377651B2 (en) 2016-10-19 2022-07-05 Flodesign Sonics, Inc. Cell therapy processes utilizing acoustophoresis
US11708572B2 (en) 2015-04-29 2023-07-25 Flodesign Sonics, Inc. Acoustic cell separation techniques and processes
US10434153B1 (en) 2015-05-20 2019-10-08 Kim Leslie O'Neill Use of car and bite technology coupled with an scFv from an antibody against human thymidine kinase 1 to specifically target tumors
CN111234027A (zh) 2015-05-21 2020-06-05 哈普恩治疗公司 三特异性结合蛋白质及使用方法
US11655452B2 (en) * 2015-06-25 2023-05-23 Icell Gene Therapeutics Inc. Chimeric antigen receptors (CARs), compositions and methods of use thereof
US11459540B2 (en) 2015-07-28 2022-10-04 Flodesign Sonics, Inc. Expanded bed affinity selection
US11474085B2 (en) 2015-07-28 2022-10-18 Flodesign Sonics, Inc. Expanded bed affinity selection
IL311107A (en) 2016-02-17 2024-04-01 Seagen Inc BCMA antibodies and their use for the treatment of cancer and immune disorders
US11085035B2 (en) 2016-05-03 2021-08-10 Flodesign Sonics, Inc. Therapeutic cell washing, concentration, and separation utilizing acoustophoresis
US11214789B2 (en) 2016-05-03 2022-01-04 Flodesign Sonics, Inc. Concentration and washing of particles with acoustics
US11623958B2 (en) 2016-05-20 2023-04-11 Harpoon Therapeutics, Inc. Single chain variable fragment CD3 binding proteins
BR112018073739A2 (pt) 2016-05-20 2019-02-26 Harpoon Therapeutics, Inc. proteína de ligação de albumina sérica de domínio único
EP4353750A3 (en) * 2016-06-24 2024-07-24 iCell Gene Therapeutics LLC Chimeric antigen receptors (cars), compositions and methods thereof
CN110494543A (zh) 2016-10-19 2019-11-22 弗洛设计声能学公司 通过声学的亲和细胞提取
WO2018144535A1 (en) 2017-01-31 2018-08-09 Novartis Ag Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
CN108395482B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20抗原嵌合抗原受体的构建及其工程化t细胞的活性鉴定
SG11201907580SA (en) 2017-02-17 2019-09-27 Hutchinson Fred Cancer Res Combination therapies for treatment of bcma-related cancers and autoimmune disorders
US11535668B2 (en) 2017-02-28 2022-12-27 Harpoon Therapeutics, Inc. Inducible monovalent antigen binding protein
MY200973A (en) 2017-04-11 2024-01-26 Inhibrx Inc Multispecific Polypeptide Constructs Having Constrained Cd3 Binding And Methods Of Using The Same
WO2018200585A1 (en) * 2017-04-26 2018-11-01 Eureka Therapeutics, Inc. Cells expressing chimeric antigen receptors and secondary effectors and uses thereof
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP3615055A1 (en) 2017-04-28 2020-03-04 Novartis AG Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
CA3061945A1 (en) 2017-05-01 2018-11-08 Juno Therapeutics, Inc. Combination of a cell therapy and an immunomodulatory compound
US12226479B2 (en) 2017-05-11 2025-02-18 The General Hospital Corporation Methods and compositions of use of CD8+ tumor infiltrating lymphocyte subtypes and gene signatures thereof
CA3063359A1 (en) 2017-05-12 2018-11-15 Harpoon Therapeutics, Inc. Mesothelin binding proteins
US10415017B2 (en) 2017-05-17 2019-09-17 Thunder Biotech, Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
AU2017414703B2 (en) * 2017-05-17 2025-02-06 Thunder Biotech Inc. Transgenic macrophages, chimeric antigen receptors, and associated methods
CN107337736B (zh) * 2017-06-06 2019-07-26 上海优卡迪生物医药科技有限公司 Octs-car双靶向嵌合抗原受体、编码基因、重组表达载体及其构建和应用
EP3638218A4 (en) 2017-06-14 2021-06-09 The Broad Institute, Inc. COMPOSITIONS AND METHOD OF TARGETING COMPLEMENTING COMPONENT 3 FOR INHIBITION OF TUMOR GROWTH
SG11202000555UA (en) 2017-06-21 2020-02-27 Icell Gene Therapeutics Llc Chimeric antigen receptors (cars), compositions and methods thereof
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
AU2018291128B2 (en) * 2017-06-30 2024-10-10 Teneobio, Inc. Anti-B-cell maturation antigen chimeric antigen receptors with human domains
US12049643B2 (en) 2017-07-14 2024-07-30 The Broad Institute, Inc. Methods and compositions for modulating cytotoxic lymphocyte activity
WO2019018525A1 (en) * 2017-07-20 2019-01-24 H. Lee Moffitt Cancer Center And Research Institute, Inc. CHIMERIC ANTIGENIC RECEPTORS BINDING TO CD123
EP3661964A1 (en) * 2017-07-31 2020-06-10 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy
WO2019046818A1 (en) * 2017-09-01 2019-03-07 Dana-Farber Cancer Institute, Inc. SPECIFIC IMMUNOGENIC PEPTIDES OF BCMA AND TACI ANTIGENS FOR THE TREATMENT OF CANCER
US20200207867A1 (en) * 2017-09-13 2020-07-02 Teneobio, Inc. Heavy chain antibodies binding to ectoenzymes
EP3689908A4 (en) * 2017-09-29 2021-09-29 Mogam Institute for Biomedical Research ANTI-BCMA ANTIBODIES WITH HIGH AFFINITY FOR BCMA AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF CANCER, INCLUDING THIS
WO2019070755A1 (en) 2017-10-02 2019-04-11 The Broad Institute, Inc. METHODS AND COMPOSITIONS FOR DETECTING AND MODULATING A GENETIC SIGNATURE OF IMMUNOTHERAPY RESISTANCE IN CANCER
IL315737A (en) * 2017-10-13 2024-11-01 Harpoon Therapeutics Inc B-cell maturation antigen-binding proteins
UA129446C2 (uk) 2017-10-13 2025-04-30 Гарпун Терап'Ютікс, Інк. Триспецифічні білки і способи їх застосування
BR112020007576A2 (pt) 2017-10-18 2020-09-24 Novartis Ag composições e métodos para degradação de proteína seletiva
BR112020008638A2 (pt) 2017-11-01 2020-10-20 Juno Therapeutics Inc receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma)
AU2018359907A1 (en) 2017-11-06 2020-05-07 Fred Hutchinson Cancer Center Combination of a cell therapy and a gamma secretase inhibitor
WO2019094955A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for targeting developmental and oncogenic programs in h3k27m gliomas
WO2019094983A1 (en) 2017-11-13 2019-05-16 The Broad Institute, Inc. Methods and compositions for treating cancer by targeting the clec2d-klrb1 pathway
US20200360431A1 (en) * 2017-11-15 2020-11-19 Novartis Ag Bcma-targeting chimeric antigen receptor, cd19-targeting chimeric antigen receptor, and combination therapies
TW201925782A (zh) 2017-11-30 2019-07-01 瑞士商諾華公司 靶向bcma之嵌合抗原受體及其用途
KR20220066413A (ko) 2017-12-14 2022-05-24 프로디자인 소닉스, 인크. 음향 트랜스듀서 구동기 및 제어기
US20190192678A1 (en) * 2017-12-18 2019-06-27 Novather, Inc. System and method for the treatment of disease using a hyperspecific modified protein system
KR20250010750A (ko) 2017-12-20 2025-01-21 포세이다 테라퓨틱스, 인크. Vcar 조성물 및 사용 방법
AU2018392080A1 (en) * 2017-12-22 2020-07-02 2Seventy Bio, Inc. Multivalent chimeric antigen receptor
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
TW201930591A (zh) 2018-01-08 2019-08-01 瑞士商諾華公司 用於與嵌合抗原受體療法併用之免疫增強rna
KR102115236B1 (ko) * 2018-01-29 2020-05-27 (주)에스엠티바이오 췌장 또는 담관계암 치료를 위한 키메라 항원 수용체
CA3090249A1 (en) 2018-01-31 2019-08-08 Novartis Ag Combination therapy using a chimeric antigen receptor
WO2019160956A1 (en) 2018-02-13 2019-08-22 Novartis Ag Chimeric antigen receptor therapy in combination with il-15r and il15
MX2020009116A (es) 2018-03-02 2020-12-07 Cdr Life Ag Proteinas triespecificas de union a antigenos.
WO2019195586A1 (en) * 2018-04-06 2019-10-10 The Regents Of The University Of California Methods of treating egfrviii expressing glioblastomas
US12090170B2 (en) 2018-04-06 2024-09-17 The Regents Of The University Of California Methods of treating glioblastomas
EP3549597A1 (en) * 2018-04-06 2019-10-09 Heinrich-Heine-Universität Düsseldorf Synthetic signalling constructs and its use
IL323061A (en) 2018-04-11 2025-10-01 Inhibrx Biosciences Inc Multispecific polypeptide constructs with forced CD3 binding and related methods and uses
US11957695B2 (en) 2018-04-26 2024-04-16 The Broad Institute, Inc. Methods and compositions targeting glucocorticoid signaling for modulating immune responses
WO2019222283A1 (en) 2018-05-14 2019-11-21 Harpoon Therapeutics, Inc. Binding moiety for conditional activation of immunoglobulin molecules
AU2019270624B2 (en) 2018-05-16 2024-05-02 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of T cell redirecting therapeutics
US20210371932A1 (en) 2018-06-01 2021-12-02 Massachusetts Institute Of Technology Methods and compositions for detecting and modulating microenvironment gene signatures from the csf of metastasis patients
US12036240B2 (en) 2018-06-14 2024-07-16 The Broad Institute, Inc. Compositions and methods targeting complement component 3 for inhibiting tumor growth
WO2019242632A1 (en) * 2018-06-19 2019-12-26 1§1Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
CN112351997B (zh) * 2018-07-20 2023-05-26 坦尼奥第二公司 与cd19结合的重链抗体
CN112789294A (zh) * 2018-07-24 2021-05-11 印希比股份有限公司 含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
AU2019318135A1 (en) * 2018-08-10 2021-03-04 Sangamo Therapeutics France New car constructs comprising TNFR2 domains
GB201813178D0 (en) * 2018-08-13 2018-09-26 Autolus Ltd Cell
ES3042082T3 (en) 2018-08-31 2025-11-18 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN109293781A (zh) * 2018-09-12 2019-02-01 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、cd19-cd20双靶向性的t细胞及其应用
US12195544B2 (en) 2018-09-21 2025-01-14 Harpoon Therapeutics, Inc. EGFR binding proteins and methods of use
CN109081870B (zh) * 2018-09-21 2021-12-03 成都阿帕克生物科技有限公司 一种抗人促绒毛膜促性腺激素β亚单位的纳米抗体及核酸分子和应用
CN109265550B (zh) * 2018-09-25 2020-09-15 华东师范大学 Bcma抗体、嵌合抗原受体和药物
EP3856771A4 (en) 2018-09-25 2022-06-29 Harpoon Therapeutics, Inc. Dll3 binding proteins and methods of use
US20210382068A1 (en) 2018-10-02 2021-12-09 Dana-Farber Cancer Institute, Inc. Hla single allele lines
CA3115089A1 (en) * 2018-10-11 2020-04-16 Inhibrx, Inc. Dll3 single domain antibodies and therapeutic compositions thereof
US20210379057A1 (en) 2018-10-16 2021-12-09 Massachusetts Institute Of Technology Nutlin-3a for use in treating a mycobacterium tuberculosis infection
BR112021000173A2 (pt) * 2018-10-26 2021-05-04 Teneobio, Inc. anticorpos de cadeia pesada com ligação a cd38
WO2020092455A2 (en) 2018-10-29 2020-05-07 The Broad Institute, Inc. Car t cell transcriptional atlas
AU2019374103A1 (en) 2018-11-01 2021-05-20 Juno Therapeutics, Inc. Chimeric antigen receptors specific for G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)
MX2021005366A (es) 2018-11-08 2021-09-10 Juno Therapeutics Inc Metodos y combinaciones para el tratamiento y modulacion de celulas t.
IL283734B2 (en) 2018-12-12 2025-03-01 Kite Pharma Inc Chimeric antigen receptors and CAR-T cells and methods of use
US20220062394A1 (en) 2018-12-17 2022-03-03 The Broad Institute, Inc. Methods for identifying neoantigens
WO2020135559A1 (en) * 2018-12-26 2020-07-02 Nanjing Legend Biotech Co., Ltd. Cd30-binding moieties, chimeric antigen receptors, and uses thereof
CN109651511B (zh) * 2018-12-26 2020-06-09 广州百暨基因科技有限公司 一种靶向bcma的嵌合抗原受体及其应用
US11739156B2 (en) 2019-01-06 2023-08-29 The Broad Institute, Inc. Massachusetts Institute of Technology Methods and compositions for overcoming immunosuppression
WO2020142815A1 (en) * 2019-01-07 2020-07-16 Celluris Participações Ltda Bispecific in tandem receptor car and method for modulating the tumoral microenvironment
CN109678961A (zh) * 2019-01-15 2019-04-26 深圳市南科生物工程有限公司 一种基于bmca纳米抗体序列的嵌合抗原受体的构建方法及其应用
AU2020212534A1 (en) 2019-01-22 2021-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
CN113727602B (zh) 2019-02-04 2023-10-03 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
KR20210134339A (ko) 2019-02-25 2021-11-09 노파르티스 아게 바이러스 전달을 위한 메조다공성 실리카 입자 조성물
EP3773918A4 (en) 2019-03-05 2022-01-05 Nkarta, Inc. ANTI-CD19 CHEMERIC ANTIGEN RECEPTORS AND THEIR USE IN IMMUNOTHERAPY
WO2020186101A1 (en) 2019-03-12 2020-09-17 The Broad Institute, Inc. Detection means, compositions and methods for modulating synovial sarcoma cells
EP3942023A1 (en) 2019-03-18 2022-01-26 The Broad Institute, Inc. Compositions and methods for modulating metabolic regulators of t cell pathogenicity
WO2020191316A1 (en) 2019-03-21 2020-09-24 Novartis Ag Car-t cell therapies with enhanced efficacy
MX2021011141A (es) 2019-03-21 2022-01-19 Regeneron Pharma Combinacion de inhibidores de la via de il-4/il-13 y ablacion de celulas plasmaticas para el tratamiento de alergia.
CN113710707B (zh) 2019-04-05 2024-05-31 特尼奥生物股份有限公司 结合于psma的重链抗体
WO2020210678A1 (en) 2019-04-12 2020-10-15 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
CN109942709B (zh) * 2019-04-22 2019-12-27 广州百暨基因科技有限公司 一种抗bcma的单域抗体及其应用
AU2020261886A1 (en) * 2019-04-22 2021-11-18 Nanjing Legend Biotech Co., Ltd. Engineered cells and uses thereof
US20220251152A1 (en) 2019-04-24 2022-08-11 Novartis Ag Compositions and methods for selective protein degradation
EP3733707A1 (en) 2019-04-30 2020-11-04 Celyad S.A. Car t-cells targeting bcma and uses thereof
US11162079B2 (en) 2019-05-10 2021-11-02 The Regents Of The University Of California Blood type O Rh-hypo-immunogenic pluripotent cells
US20220235340A1 (en) 2019-05-20 2022-07-28 The Broad Institute, Inc. Novel crispr-cas systems and uses thereof
JP7584453B2 (ja) * 2019-06-04 2024-11-15 ザ ジェネラル ホスピタル コーポレイション Ｔａｃｉを標的とする抗体及びキメラ抗原受容体
AU2020307667A1 (en) * 2019-06-27 2022-01-20 Crispr Therapeutics Ag Use of chimeric antigen receptor T cells and NK cell inhibitors for treating cancer
WO2021030627A1 (en) 2019-08-13 2021-02-18 The General Hospital Corporation Methods for predicting outcomes of checkpoint inhibition and treatment thereof
US12421557B2 (en) 2019-08-16 2025-09-23 The Broad Institute, Inc. Methods for predicting outcomes and treating colorectal cancer using a cell atlas
CN110540997B (zh) * 2019-08-29 2024-02-13 浙江煦顼技术有限公司 靶向bcma嵌合抗原受体、核酸序列、载体及应用
JOP20220049A1 (ar) * 2019-08-30 2023-01-30 Janssen Biotech Inc مشرعات وتركيبات car t خاصة بمركب نضج الخلايا البائية
WO2021041922A1 (en) 2019-08-30 2021-03-04 The Broad Institute, Inc. Crispr-associated mu transposase systems
WO2021043169A1 (zh) * 2019-09-02 2021-03-11 成都盛世君联生物技术有限公司 特异性结合b细胞成熟抗原的抗体及其用途
WO2021054789A1 (ko) * 2019-09-18 2021-03-25 주식회사 에스엘바이젠 신규 키메라 항원 수용체 암호화 유전자가 형질도입된 유전자 변형 nk 세포주 및 그의 용도
US12297426B2 (en) 2019-10-01 2025-05-13 The Broad Institute, Inc. DNA damage response signature guided rational design of CRISPR-based systems and therapies
US12394502B2 (en) 2019-10-02 2025-08-19 The General Hospital Corporation Method for predicting HLA-binding peptides using protein structural features
US12195725B2 (en) 2019-10-03 2025-01-14 Dana-Farber Cancer Institute, Inc. Compositions and methods for modulating and detecting tissue specific TH17 cell pathogenicity
US11981922B2 (en) 2019-10-03 2024-05-14 Dana-Farber Cancer Institute, Inc. Methods and compositions for the modulation of cell interactions and signaling in the tumor microenvironment
US11793787B2 (en) 2019-10-07 2023-10-24 The Broad Institute, Inc. Methods and compositions for enhancing anti-tumor immunity by targeting steroidogenesis
EP4048292A4 (en) * 2019-10-21 2024-06-19 Purdue Research Foundation Engineered natural killer cells and methods for using the same in immunotherapy and autophagy inhibition techniques
CN114729041B (zh) 2019-10-22 2024-12-31 美国政府(由卫生和人类服务部的部长所代表) 用于治疗多种实体瘤的靶向b7h3（cd276）的高亲和力纳米抗体
US11844800B2 (en) 2019-10-30 2023-12-19 Massachusetts Institute Of Technology Methods and compositions for predicting and preventing relapse of acute lymphoblastic leukemia
WO2021091945A1 (en) 2019-11-05 2021-05-14 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy of multiple myeloma
US20230058044A1 (en) * 2019-11-26 2023-02-23 Ramot At Tel-Aviv University Ltd. Chimeric antigen receptor to carbohydrate antigens
CA3163104A1 (en) 2019-11-26 2021-06-03 Novartis Ag Chimeric antigen receptors and uses thereof
EP4077398A4 (en) * 2019-12-16 2024-04-10 Legend Biotech Ireland Limited SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
CN111171158B (zh) * 2020-01-17 2020-10-30 南京蓝盾生物科技有限公司 同时靶向bcma和cd38的嵌合抗原受体及其应用
US12165747B2 (en) 2020-01-23 2024-12-10 The Broad Institute, Inc. Molecular spatial mapping of metastatic tumor microenvironment
CN115397973A (zh) * 2020-01-30 2022-11-25 免疫生物公司 表达car的nk细胞消除bcma阳性恶性肿瘤
US20240261329A1 (en) * 2020-02-13 2024-08-08 Sichuan University Chimeric antigen receptor and use thereof
IL295421A (en) * 2020-02-14 2022-10-01 Univ Leland Stanford Junior Chimeric antigen receptors with cd2 activation
BR112022016633A2 (pt) 2020-02-27 2022-12-13 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
US20230256017A1 (en) 2020-02-27 2023-08-17 Jennifer Brogdon Methods of making chimeric antigen receptor-expressing cells
US20210332448A1 (en) * 2020-03-09 2021-10-28 Janssen Pharmaceutica Nv Compositions and methods for quantifying integration of recombinant vector nucleic acid
CN113402612A (zh) * 2020-03-17 2021-09-17 西比曼生物科技（香港）有限公司 靶向cd19和cd20的联合嵌合抗原受体及其应用
KR20230009386A (ko) 2020-04-10 2023-01-17 주노 쎄러퓨티크스 인코퍼레이티드 Ｂ-세포 성숙 항원을 표적화하는 키메라 항원 수용체로 조작된 세포 요법 관련 방법 및 용도
EP4142723A2 (en) 2020-04-28 2023-03-08 Juno Therapeutics, Inc. Combination of bcma-directed t cell therapy and an immunomodulatory compound
CN115715220A (zh) 2020-04-29 2023-02-24 特尼奥生物股份有限公司 具有经修饰重链恒定区的多特异性重链抗体
WO2021223705A1 (en) * 2020-05-06 2021-11-11 Gracell Biotechnologies (Shanghai) Co., Ltd. Compositions and methods for t cell engineering
CN111607565A (zh) * 2020-06-04 2020-09-01 河南大学 一种北平顶猴t细胞的体外扩增方法
JP2023530238A (ja) * 2020-06-08 2023-07-14 ヤンセン バイオテツク，インコーポレーテツド キメラ抗原発現免疫細胞のインビトロ腫瘍殺傷活性を決定するための細胞ベースのアッセイ
IL298780A (en) 2020-06-08 2023-02-01 Minerva Biotechnologies Corp Anti-nme antibody and method of treating cancer or cancer metastasis
US20230332104A1 (en) 2020-06-11 2023-10-19 Novartis Ag Zbtb32 inhibitors and uses thereof
EP4168437A1 (en) 2020-06-22 2023-04-26 Lentigen Technology, Inc. Compositions and methods for treating cancer with tslpr-cd19 or tslpr-cd22 immunotherapy
CN116075318A (zh) 2020-06-26 2023-05-05 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
CN114222761B (zh) * 2020-07-14 2024-02-20 浙江道尔生物科技有限公司 一种抗cld18a2的单域抗体
US20230272104A1 (en) * 2020-07-16 2023-08-31 Nanjing Legend Biotech Co., Ltd. Cd20 binding molecules and uses thereof
KR20230038706A (ko) * 2020-07-16 2023-03-21 난징 레전드 바이오테크 씨오., 엘티디. Cd19 결합 분자 및 이의 용도
EP4182352A4 (en) * 2020-07-16 2025-03-19 Legend Biotech Ireland Limited Cd22 binding molecules and uses thereof
AU2021308745A1 (en) * 2020-07-16 2023-02-16 Legend Biotech Ireland Limited Multispecific chimeric antigen receptors and uses thereof
CN111848798B (zh) * 2020-07-27 2022-05-13 源道隆（苏州）医学科技有限公司 可结合bcma的纳米抗体及其应用
CA3187472A1 (en) * 2020-07-29 2022-02-03 Scott MCCOMB Anti-cd22 single domain antibodies and therapeutic constructs
CN111909271B (zh) * 2020-08-12 2021-03-23 深圳市茵冠生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及其应用
US20230340146A1 (en) 2020-08-13 2023-10-26 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Igg4 hinge-containing chimeric antigen receptors targeting glypican-1 (gpc1) for treating solid tumors
EP4201960A4 (en) 2020-08-20 2024-09-04 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. BCMA-BINDING SINGLE MOLECULE WITH VARIABLE DOMAIN AND ANTIGEN-BINDING MOLECULE
US20230193292A1 (en) 2020-08-20 2023-06-22 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bcma-binding single variable structural domain and antigen-binding molecule
US20230302155A1 (en) 2020-08-21 2023-09-28 Novartis Ag Compositions and methods for in vivo generation of car expressing cells
CN112062864A (zh) * 2020-09-18 2020-12-11 樊克兴 靶向bcma肿瘤抗原受体修饰t细胞的制备方法和应用
CN111925451B (zh) * 2020-10-12 2021-01-29 佑仁细胞工程(浙江)有限公司 一种靶向bcma的嵌合抗原受体(car)及其应用
CN112251412B (zh) * 2020-10-12 2023-03-28 汤朝阳 一种靶向bcma的嵌合抗原受体t细胞及其应用
WO2022093745A1 (en) 2020-10-26 2022-05-05 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting sars coronavirus spike protein and uses thereof
CN112028996B (zh) * 2020-10-30 2021-01-22 南京北恒生物科技有限公司 靶向bcma的单域抗体及其用途
KR20230090367A (ko) 2020-11-04 2023-06-21 주노 쎄러퓨티크스 인코퍼레이티드 변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
WO2022116086A1 (en) * 2020-12-03 2022-06-09 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2022120160A1 (en) 2020-12-04 2022-06-09 Celgene Corporation Uses of chimeric antigen receptor (car) t-cell therapies in combination with inhibitors of inflammation-related soluble factors
TW202237639A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 鳥苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
TW202237638A (zh) 2020-12-09 2022-10-01 日商武田藥品工業股份有限公司 烏苷酸環化酶ｃ（ｇｃｃ）抗原結合劑之組成物及其使用方法
JP2024500189A (ja) 2020-12-21 2024-01-04 アロジーン セラピューティクス，インコーポレイテッド プロテアーゼ活性化ｃｄ４５ゲートｃａｒ
CN116390954A (zh) * 2020-12-29 2023-07-04 宁波茂行生物医药科技有限公司 靶向bcma的单域抗体
KR20230137900A (ko) 2020-12-31 2023-10-05 사나 바이오테크놀로지, 인크. Car-t 활성을 조정하기 위한 방법 및 조성물
CN112321713B (zh) * 2020-12-31 2021-05-25 北京艺妙神州医药科技有限公司 一种抗bcma的抗体及其应用
WO2022150731A1 (en) 2021-01-11 2022-07-14 Sana Biotechnology, Inc. Use of cd8-targeted viral vectors
CN114149505B (zh) * 2021-01-12 2022-11-04 北京门罗生物科技有限公司 治疗b细胞相关疾病的免疫细胞、制备方法及其应用
US20240091356A1 (en) * 2021-01-27 2024-03-21 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bi-specific car t ccells for b cell malignancies
KR20230142470A (ko) 2021-01-29 2023-10-11 알로젠 테라퓨틱스 인코포레이티드 동종이계 세포 산물의 T 세포 인식을 완화하기 위한TAP2, NLRC5, β2m, TRAC, RFX5, RFXAP, 및 RFXANK 중 하나 이상의 녹다운 또는 녹아웃
KR20230146032A (ko) 2021-02-15 2023-10-18 다케다 야쿠힌 고교 가부시키가이샤 Tgf-b 신호전달을 조절하기 위한 세포 치료 조성물 및 방법
WO2022183160A1 (en) * 2021-02-25 2022-09-01 H. Lee Moffitt Cancer Center And Research Institute Inc. Methods for treating cd83-expressing cancer
US20240108654A1 (en) 2021-03-03 2024-04-04 Juno Therapeutics, Inc. Combination of a t cell therapy and a dgk inhibitor
AU2022255709A1 (en) * 2021-04-06 2023-09-28 Teneobio, Inc. Anti-cd19 antibodies and car-t structures
CN117730091A (zh) * 2021-04-13 2024-03-19 悟境股份有限公司 改善的嵌合抗原受体及其用途
EP4324853A4 (en) 2021-04-15 2025-07-16 Chia Tai Tianqing Pharmaceutical Group Co Ltd MULTI-SPECIFIC ANTIBODY TARGETING BCMA
IL307612A (en) 2021-04-16 2023-12-01 Celgene Corp Combined therapies with BCMA-directed T-cell therapy
CN117337303A (zh) * 2021-04-16 2024-01-02 特尼奥生物股份有限公司 抗cd20抗体及car-t结构
AU2022257093A1 (en) 2021-04-16 2023-11-02 Celgene Corporation T cell therapy in patients who have had prior stem cell transplant
CN118056008A (zh) 2021-04-27 2024-05-17 诺华股份有限公司 病毒载体生产系统
US20240218055A1 (en) 2021-04-29 2024-07-04 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Lassa virus-specific nanobodies and methods of their use
WO2022228579A1 (en) * 2021-04-30 2022-11-03 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting gpc3 and methods of use thereof
CN117916256A (zh) 2021-05-06 2024-04-19 朱诺治疗学有限公司 用于刺激和转导t细胞的方法
TW202309522A (zh) 2021-05-11 2023-03-01 美商健生生物科技公司 用於監測復發性及／或難治性多發性骨髓瘤之治療的方法及組成物
AR125827A1 (es) 2021-05-11 2023-08-16 Janssen Biotech Inc Métodos para minimizar la neurotoxicidad asociada a la terapia con células t del receptor de antígeno quimérico (car)
CA3218215A1 (en) * 2021-05-19 2022-11-24 Biliang HU Bi-specific chimeric antigen receptors and genetically engineered immune cells expressing such
US20240252642A1 (en) 2021-05-19 2024-08-01 Sana Biotechnology, Inc. Hypoimmunogenic rhd negative primary t cells
KR20240013135A (ko) 2021-05-27 2024-01-30 사나 바이오테크놀로지, 인크. 조작된 hla-e 또는 hla-g를 포함하는 저면역원성 세포
US20240270851A1 (en) 2021-06-09 2024-08-15 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Cross species single domain antibodies targeting pd-l1 for treating solid tumors
EP4362957A1 (en) 2021-07-01 2024-05-08 Indapta Therapeutics, Inc. Engineered natural killer (nk) cells and related methods
EP4370541A1 (en) 2021-07-14 2024-05-22 2seventy bio, Inc. Engineered t cell receptors fused to binding domains from antibodies
AU2022309875A1 (en) 2021-07-14 2024-01-25 Sana Biotechnology, Inc. Altered expression of y chromosome-linked antigens in hypoimmunogenic cells
TW202321457A (zh) 2021-08-04 2023-06-01 美商薩那生物科技公司 靶向ｃｄ４之病毒載體之用途
IL310702A (en) 2021-08-11 2024-04-01 Sana Biotechnology Inc Inducible systems for altering gene expression in hypoimmunogenic cells
CN113651893B (zh) * 2021-08-12 2023-08-01 上海生物制品研究所有限责任公司 联合her2和meso双靶点car-t载体及其构建方法和在癌症中的应用
AU2022326908A1 (en) * 2021-08-12 2024-03-28 Cellogen Therapeutics Pvt. Ltd. Chimeric antigen receptors (car) for b cell malignancies
WO2023021477A1 (en) 2021-08-20 2023-02-23 Novartis Ag Methods of making chimeric antigen receptor–expressing cells
US11970548B2 (en) * 2021-08-27 2024-04-30 Innovative Cellular Therapeutics Holdings, Ltd. Nanobody target GCC and uses in chimeric antigen receptor cell therapy
US11359012B1 (en) 2021-08-27 2022-06-14 Nanjing Kaedi Biotherapeutics Ltd. Specific chimeric antigen receptor cells targeting human CLDN18A2, preparation method and application thereof
MX2024003808A (es) * 2021-09-29 2024-06-11 Modex Therapeutics Inc Polipeptidos de union a antigeno, complejos de polipeptidos de union a antigeno y metodos de uso de los mismos.
EP4413043A4 (en) * 2021-10-07 2025-11-12 Nat Res Council Canada Single-domain anti-BCMA antibodies and therapeutic constructs
EP4419117A1 (en) 2021-10-22 2024-08-28 Sana Biotechnology, Inc. Methods of engineering allogeneic t cells with a transgene in a tcr locus and associated compositions and methods
WO2023076881A1 (en) 2021-10-26 2023-05-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting the s2 subunit of sars-cov-2 spike protein
CN119120424A (zh) 2021-11-02 2024-12-13 辉大(上海)生物科技有限公司 一种CRISPR-Cas12i系统
EP4426339A1 (en) 2021-11-03 2024-09-11 Celgene Corporation Chimeric antigen receptors specific for b-cell maturation antigen for use in treating myeloma
MX2024005406A (es) 2021-11-03 2024-08-06 Janssen Biotech Inc Reduccion de corticosteroides en el tratamiento con anticuerpos anti-cd38.
AU2022381186A1 (en) 2021-11-04 2024-05-16 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2023077343A1 (en) 2021-11-04 2023-05-11 Janssen Biotech, Inc. Bcma-targeted car-t cell therapy for multiple myeloma
US20250017962A1 (en) 2021-11-09 2025-01-16 The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Igg4 hinge-containing chimeric antigen receptors targeting glypican-3 (gpc3) and use thereof
CN115466331B (zh) * 2021-11-18 2023-05-30 合源生物科技(天津)有限公司 靶向bcma的嵌合抗原受体及其应用
EP4446341A1 (en) * 2021-12-07 2024-10-16 Innovent Biologics (Suzhou) Co., Ltd. Antibody binding to bcma and use thereof
WO2023109257A1 (zh) * 2021-12-16 2023-06-22 浙江瑞加美生物科技有限公司 人源化的bcma抗体和bcma-car-t/bcma-car-dnt细胞
EP4448549A2 (en) 2021-12-17 2024-10-23 Sana Biotechnology, Inc. Modified paramyxoviridae fusion glycoproteins
WO2023115041A1 (en) 2021-12-17 2023-06-22 Sana Biotechnology, Inc. Modified paramyxoviridae attachment glycoproteins
AU2022422147A1 (en) 2021-12-23 2024-07-04 Sana Biotechnology, Inc. Chimeric antigen receptor (car) t cells for treating autoimmune disease and associated methods
CA3241112A1 (en) * 2021-12-29 2023-07-06 Arash Hatefi Single-domain high affinity antibodies and methods of use thereof
EP4463135A2 (en) 2022-01-10 2024-11-20 Sana Biotechnology, Inc. Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
WO2023147515A1 (en) 2022-01-28 2023-08-03 Juno Therapeutics, Inc. Methods of manufacturing cellular compositions
US20250152709A1 (en) 2022-02-01 2025-05-15 Sana Biotechnology, Inc. Cd3-targeted lentiviral vectors and uses thereof
US20250144235A1 (en) 2022-02-02 2025-05-08 Sana Biotechnology, Inc. Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
EP4479140A1 (en) 2022-02-15 2024-12-25 The United States of America, as represented by The Secretary, Department of Health and Human Services Cd28 hinge and transmembrane containing chimeric antigen receptors targeting gpc2 and use thereof
KR20240155390A (ko) 2022-02-17 2024-10-28 사나 바이오테크놀로지, 인크. 조작된 cd47 단백질 및 이의 용도
KR20240158888A (ko) 2022-02-28 2024-11-05 얀센 바이오테크 인코포레이티드 다발성 골수종을 위한 bcma를 표적으로 하는 car-t 세포 요법
WO2023193015A1 (en) 2022-04-01 2023-10-05 Sana Biotechnology, Inc. Cytokine receptor agonist and viral vector combination therapies
CN119546327A (zh) 2022-04-08 2025-02-28 再生元制药公司 多部分受体和信号传导复合物
US20250297282A1 (en) 2022-05-05 2025-09-25 Juno Therapeutics Gmbh Viral-binding protein and related reagents, articles, and methods of use
CN119212724A (zh) * 2022-05-09 2024-12-27 上海先博生物科技有限公司 工程化免疫效应细胞及其与CBL-b抑制剂联用的应用
WO2023220641A2 (en) 2022-05-11 2023-11-16 Juno Therapeutics, Inc. Methods and uses related to t cell therapy and production of same
WO2023220655A1 (en) 2022-05-11 2023-11-16 Celgene Corporation Methods to overcome drug resistance by re-sensitizing cancer cells to treatment with a prior therapy via treatment with a t cell therapy
WO2023230581A1 (en) 2022-05-25 2023-11-30 Celgene Corporation Methods of manufacturing t cell therapies
US20250345432A1 (en) 2022-05-25 2025-11-13 Celgene Corporation Method for predicting response to a t cell therapy
AU2023276514A1 (en) * 2022-05-27 2024-12-05 Suzhou Immunofoco Biotechnology Co., Ltd Chimeric antigen receptor containing cldn18.2 single domain antibody and application thereof
EP4536710A1 (en) * 2022-06-13 2025-04-16 The Regents of the University of California Humanized antibodies to human integrin avb8
US12297285B2 (en) * 2022-06-24 2025-05-13 Orna Therapeutics, Inc. Circular RNA encoding chimeric antigen receptors targeting BCMA
CN114805582B (zh) * 2022-06-29 2022-10-04 上海恒润达生生物科技股份有限公司 抗Trop2纳米抗体及其用途
CA3259982A1 (en) 2022-06-30 2024-01-04 Indapta Therapeutics Inc COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
WO2024026377A1 (en) 2022-07-27 2024-02-01 Sana Biotechnology, Inc. Methods of transduction using a viral vector and inhibitors of antiviral restriction factors
WO2024026455A2 (en) * 2022-07-29 2024-02-01 Shoreline Biosciences, Inc. Methods and compositions for generating chimeric antigen receptor-monocytes/macrophages
US20240042030A1 (en) 2022-07-29 2024-02-08 Allogene Therapeutics, Inc. Engineered cells with reduced gene expression to mitigate immune cell recognition
EP4565262A2 (en) 2022-08-05 2025-06-11 Juno Therapeutics, Inc. Chimeric antigen receptors specific for gprc5d and bcma
WO2024050399A1 (en) 2022-09-01 2024-03-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies targeting hpv e6/e7 oncogenic peptide/mhc complexes
JP2025531850A (ja) 2022-09-08 2025-09-25 ジュノー セラピューティクス インコーポレイテッド Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
EP4590688A1 (en) 2022-09-21 2025-07-30 Sana Biotechnology, Inc. Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
CN115925947B (zh) * 2022-09-27 2023-08-22 上海百英生物科技股份有限公司 一种亲和力成熟方法及抗人pd-l1单域抗体的亲和力成熟
WO2024077256A1 (en) 2022-10-07 2024-04-11 The General Hospital Corporation Methods and compositions for high-throughput discovery ofpeptide-mhc targeting binding proteins
EP4602174A1 (en) 2022-10-13 2025-08-20 Sana Biotechnology, Inc. Viral particles targeting hematopoietic stem cells
WO2024089639A1 (en) 2022-10-26 2024-05-02 Novartis Ag Lentiviral formulations
CN117384299B (zh) * 2022-11-01 2024-04-30 邦恩泰(山东)生物医药科技集团股份有限公司 靶向bcma和/或fcrh5的嵌合抗原受体、car-t细胞及其应用
WO2024097905A1 (en) 2022-11-02 2024-05-10 Celgene Corporation Methods of treatment with t cell therapy and immunomodulatory agent maintenance therapy
EP4612187A1 (en) * 2022-11-02 2025-09-10 Legend Biotech USA Inc. Bcma-targeted car-t cell therapy of multiple myeloma
WO2024097979A1 (en) * 2022-11-04 2024-05-10 Dana-Farber Cancer Institute, Inc. Bcma vh-only cars
WO2024100604A1 (en) 2022-11-09 2024-05-16 Juno Therapeutics Gmbh Methods for manufacturing engineered immune cells
EP4627096A1 (en) 2022-12-02 2025-10-08 Sana Biotechnology, Inc. Lipid particles with cofusogens and methods of producing and using the same
EP4630043A1 (en) 2022-12-06 2025-10-15 Dynamic Cell Therapies, Inc. Immune-activating complexes
WO2024123835A1 (en) 2022-12-06 2024-06-13 Dynamic Cell Therapies, Inc. Engineered switches for immune cell activity and methods of use thereof
WO2024124044A1 (en) 2022-12-07 2024-06-13 The Brigham And Women’S Hospital, Inc. Compositions and methods targeting sat1 for enhancing anti¬ tumor immunity during tumor progression
CN121100267A (zh) 2022-12-09 2025-12-09 朱诺治疗学股份有限公司 使用全息成像预测细胞表型的机器学习方法
KR20240094169A (ko) * 2022-12-13 2024-06-25 진셀비티 주식회사 B-세포 성숙 항원을 표적화하는 신규한 키메라 항원 수용체 및 이의 용도
CN115947853B (zh) * 2022-12-26 2024-06-28 河北森朗生物科技有限公司 靶向bcma的纳米抗体、嵌合抗原受体及其应用
EP4658675A1 (en) 2023-02-03 2025-12-10 C3S2 GmbH Methods for non-viral manufacturing of engineered immune cells
WO2024168192A1 (en) 2023-02-10 2024-08-15 Celgene Corporation Assessment of bcma in biological samples
CN120752259A (zh) 2023-02-22 2025-10-03 阿斯利康(瑞典)有限公司 用b细胞成熟抗原(bcma)的嵌合抗原受体治疗疾病的组合物和方法
WO2024206209A1 (en) * 2023-03-27 2024-10-03 Modernatx, Inc. Anti-cd38, anti-bcma, anti-gprc5d, and anti-fcrh5 antibodies and uses to treat various diseases such as cancer
CN116640229B (zh) * 2023-04-10 2024-01-30 中国人民解放军总医院第五医学中心 一种低pH靶向性CAR-T细胞的构建及应用
WO2024220574A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
WO2024220598A2 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Lentiviral vectors with two or more genomes
WO2024220560A1 (en) 2023-04-18 2024-10-24 Sana Biotechnology, Inc. Engineered protein g fusogens and related lipid particles and methods thereof
CA3205511A1 (en) * 2023-04-19 2025-03-17 Janssen Biotech Inc Bcma-targeted car-t cell therapy for multiple myeloma
WO2024238346A1 (en) 2023-05-12 2024-11-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Single domain antibodies that specifically bind the s2 subunit of sars-cov-2 spike protein and compositions and uses thereof
AU2024274792A1 (en) 2023-05-23 2025-10-23 Sana Biotechnology, Inc. Tandem fusogens and related lipid particles
US12311033B2 (en) 2023-05-31 2025-05-27 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117986387A (zh) * 2023-05-31 2024-05-07 四川大学华西医院 一种新型小型化car设计及制备方法和应用
WO2025006799A1 (en) 2023-06-27 2025-01-02 Capstan Therapeutics, Inc. Extracorporeal and ex vivo engineering of select cell populations from peripheral blood
CN116789859B (zh) * 2023-06-29 2024-02-23 徐州医科大学 一种用于评价bcma靶向car-t细胞药效的靶细胞及其应用
WO2025019228A1 (en) 2023-07-20 2025-01-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fully human monoclonal antibodies and chimeric antigen receptors against cd276 for the treatment of solid tumors
WO2025029930A1 (en) 2023-07-31 2025-02-06 Legend Biotech Ireland Limited Cells overexpressing cd31 and methods of use thereof
WO2025043172A1 (en) 2023-08-23 2025-02-27 Sana Biotechnology, Inc. Modified cd47 proteins and their uses
GR1010884B (el) * 2023-08-30 2025-02-19 Janssen Biotech, Inc., Θεραπεια τ κυτταρων με χιμαιρικο υποδοχεα αντιγονου (car) με στοχευμενο αντιγονο ωριμανσης των β κυτταρων (bcma) για πολλαπλο μυελωμα
WO2025054202A1 (en) 2023-09-05 2025-03-13 Sana Biotechnology, Inc. Method of screening a sample comprising a transgene with a unique barcode
WO2025059162A1 (en) 2023-09-11 2025-03-20 Dana-Farber Cancer Institute, Inc. Car-engager containing il-2 variants to enhance the functionality of car t cells
WO2025059533A1 (en) 2023-09-13 2025-03-20 The Broad Institute, Inc. Crispr enzymes and systems
WO2025067472A1 (en) * 2023-09-27 2025-04-03 Nanjing Legend Biotech Co., Ltd. Methods of culturing gamma delta t cells
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250213690A1 (en) 2023-10-05 2025-07-03 Janssen Biotech, Inc. Methods in lentiviral manufacturing for production of car-t cell drug products
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025096560A1 (en) 2023-10-30 2025-05-08 Allogene Therapeutics, Inc. Engineered cells
WO2025097055A2 (en) 2023-11-02 2025-05-08 The Broad Institute, Inc. Compositions and methods of use of t cells in immunotherapy
WO2025096878A1 (en) 2023-11-02 2025-05-08 Capstan Therapeutics, Inc. Rna for in vivo transfection with increased expression
GB202317065D0 (en) 2023-11-07 2023-12-20 Coding Bio Ltd BCMA binding molecules
WO2025098446A1 (zh) * 2023-11-07 2025-05-15 赛斯尔擎生物技术（上海）有限公司 抗bcma单域抗体及其应用
CN120025440A (zh) * 2023-11-21 2025-05-23 南京融捷康生物科技有限公司 一种抗Nkp46的单域抗体及其用途
WO2025117544A1 (en) 2023-11-29 2025-06-05 The Broad Institute, Inc. Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
WO2025129201A1 (en) 2023-12-15 2025-06-19 Capstan Therapeutics, Inc. Humanized anti-cd8 antibodies and uses thereof
WO2025130984A1 (en) * 2023-12-20 2025-06-26 Overland Therapeutics (Us) Inc. Single domain antibodies for bcma
WO2025151838A1 (en) 2024-01-12 2025-07-17 Sana Biotechnology, Inc. Safety switches to control in vitro and in vivo proliferation of cell therapy products
KR102869233B1 (ko) * 2024-01-24 2025-10-15 주식회사 박셀바이오 Bcma 특이적 키메라 항원 수용체를 포함하는 신규한 골수 침윤 림프구 집단 및 이의 제조방법
US20250242056A1 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Methods and compositions for using plasma cell depleting agents and/or b cell depleting agents to suppress host anti-aav antibody response and enable aav transduction and re-dosing
WO2025160340A2 (en) 2024-01-26 2025-07-31 Regeneron Pharmaceuticals, Inc. Combination immunosuppression for inhibiting an immune response and enabling immunogen administration and re-administration
WO2025170902A1 (en) 2024-02-05 2025-08-14 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
WO2025171388A1 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens with modified domains and related methods and uses
WO2025171383A2 (en) 2024-02-09 2025-08-14 Dispatch Biotherapeutics, Inc. Engineered cancer antigens and related methods and uses
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025184567A1 (en) 2024-03-01 2025-09-04 Regeneron Pharmaceuticals, Inc. Methods and compositions for re-dosing aav using anti-cd40 antagonistic antibody to suppress host anti-aav antibody response
WO2025184529A1 (en) 2024-03-01 2025-09-04 Sana Biotechnology, Inc. Viral particles with fusogen display and related compositions and methods
CN117866904B (zh) * 2024-03-12 2024-06-07 北京贝来药业有限公司 基于单域抗体基因修饰的干细胞对于多种的疾病的制药用途
WO2025193685A1 (en) 2024-03-12 2025-09-18 Legend Biotech Usa Inc. Bcma-targeted car-t cell therapy for multiple myeloma
CN117866903B (zh) * 2024-03-12 2024-06-04 北京贝来药业有限公司 单域抗体修饰的干细胞及其在疾病治疗中用途
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025221781A2 (en) 2024-04-15 2025-10-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting fgfr4 and/or cd276 and use thereof for the treatment of cancer
WO2025231372A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025231408A2 (en) 2024-05-03 2025-11-06 Janssen Biotech, Inc. Methods for treating multiple myeloma with car-t cells and bispecific antibodies
WO2025232812A1 (en) * 2024-05-08 2025-11-13 Shanghai Vitalgen Biopharma Co., Ltd. Biomolecule conjugated lipid nanoparticles
WO2025235598A1 (en) 2024-05-09 2025-11-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting glypican-2 and/or cd276 and their use for treating solid tumors
WO2025240496A1 (en) 2024-05-14 2025-11-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Natural killer cells expressing a mesothelin-targeted chimeric antigen receptor and interleukin-15 for the treatment of solid tumors

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154453A1 (en) * 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
WO2013123061A1 (en) * 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
WO2014153270A1 (en) * 2013-03-16 2014-09-25 Novartis Ag Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells
CN104136458A (zh) * 2012-02-22 2014-11-05 宾夕法尼亚大学董事会 在第二代嵌合抗原受体中cd2信号传导结构域的使用
CN104583230A (zh) * 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性

Family Cites Families (194)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
FR901228A (fr) 1943-01-16 1945-07-20 Deutsche Edelstahlwerke Ag Système d'aimant à entrefer annulaire
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4657760A (en) 1979-03-20 1987-04-14 Ortho Pharmaceutical Corporation Methods and compositions using monoclonal antibody to human T cells
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US5206344A (en) 1985-06-26 1993-04-27 Cetus Oncology Corporation Interleukin-2 muteins and polymer conjugation thereof
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5606040A (en) 1987-10-30 1997-02-25 American Cyanamid Company Antitumor and antibacterial substituted disulfide derivatives prepared from compounds possessing a methyl-trithio group
US5770701A (en) 1987-10-30 1998-06-23 American Cyanamid Company Process for preparing targeted forms of methyltrithio antitumor agents
EP0435911B1 (en) 1988-09-23 1996-03-13 Cetus Oncology Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
WO1990005144A1 (en) 1988-11-11 1990-05-17 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
CA2026147C (en) 1989-10-25 2006-02-07 Ravi J. Chari Cytotoxic agents comprising maytansinoids and their therapeutic use
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5508192A (en) 1990-11-09 1996-04-16 Board Of Regents, The University Of Texas System Bacterial host strains for producing proteolytically sensitive polypeptides
US5264365A (en) 1990-11-09 1993-11-23 Board Of Regents, The University Of Texas System Protease-deficient bacterial strains for production of proteolytically sensitive polypeptides
WO1992009690A2 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with altered binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
WO1993006217A1 (en) 1991-09-19 1993-04-01 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab')2 ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
ATE419355T1 (de) 1992-02-06 2009-01-15 Novartis Vaccines & Diagnostic Marker für krebs und biosynthetisches bindeprotein dafür
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
WO1994029351A2 (en) 1993-06-16 1994-12-22 Celltech Limited Antibodies
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US5639635A (en) 1994-11-03 1997-06-17 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
EP0739981A1 (en) 1995-04-25 1996-10-30 Vrije Universiteit Brussel Variable fragments of immunoglobulins - use for therapeutic or veterinary purposes
JP4312259B2 (ja) 1995-04-27 2009-08-12 アムジェン フレモント インク． 免疫したゼノマウス（ＸｅｎｏＭｏｕｓｅ）に由来するヒト抗体
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US5714586A (en) 1995-06-07 1998-02-03 American Cyanamid Company Methods for the preparation of monomeric calicheamicin derivative/carrier conjugates
US5712374A (en) 1995-06-07 1998-01-27 American Cyanamid Company Method for the preparation of substantiallly monomeric calicheamicin derivative/carrier conjugates
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
AU2660397A (en) 1996-04-05 1997-10-29 Board Of Regents, The University Of Texas System Methods for producing soluble, biologically-active disulfide bond-containing eukaryotic proteins in bacterial cells
CA2258518C (en) 1996-06-27 2011-11-22 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
DE69738539T2 (de) 1996-12-03 2009-03-26 Amgen Fremont Inc. Vollkommen humane Antikörper die EGFR binden
US6083715A (en) 1997-06-09 2000-07-04 Board Of Regents, The University Of Texas System Methods for producing heterologous disulfide bond-containing polypeptides in bacterial cells
EP0994903B1 (en) 1997-06-24 2005-05-25 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
AU759779B2 (en) 1997-10-31 2003-05-01 Genentech Inc. Methods and compositions comprising glycoprotein glycoforms
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
JP4460155B2 (ja) 1997-12-05 2010-05-12 ザ・スクリプス・リサーチ・インステイチユート マウス抗体のヒト化
WO1999037681A2 (en) 1998-01-26 1999-07-29 Unilever Plc Method for producing antibody fragments
DE69937291T2 (de) 1998-04-02 2008-07-10 Genentech, Inc., South San Francisco Antikörpervarianten und fragmente davon
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP4334141B2 (ja) 1998-04-20 2009-09-30 グリカート バイオテクノロジー アクチェンゲゼルシャフト 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
MXPA01005425A (es) 1998-12-01 2002-04-24 Genentech Inc Polipeptidos de transmembrana y secretados y acidos nucleicos que codifican los mismos.
BR0008758A (pt) 1999-01-15 2001-12-04 Genentech Inc Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
WO2000043507A1 (en) 1999-01-19 2000-07-27 Unilever Plc Method for producing antibody fragments
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
JP2002541845A (ja) 1999-04-16 2002-12-10 セルテック セラピューティックス リミテッド 合成膜貫通成分
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
CA2395660A1 (en) 1999-12-29 2001-07-12 Immunogen, Inc. Cytotoxic agents comprising modified doxorubicins and daunorubicins and their therapeutic use
DK1257632T3 (da) 2000-02-24 2008-01-28 Xcyte Therapies Inc Samtidig stimulering og opkoncentrering af celler
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
DK1272647T3 (en) 2000-04-11 2014-12-15 Genentech Inc Multivalent antibodies and uses thereof
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EA013563B1 (ru) 2000-10-06 2010-06-30 Киова Хакко Кирин Ко., Лтд. Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
DK1354034T3 (da) 2000-11-30 2008-03-25 Medarex Inc Transgene transchromosomale gnavere til fremstilling af humane antistoffer
GB0110029D0 (en) 2001-04-24 2001-06-13 Grosveld Frank Transgenic animal
US20060073141A1 (en) 2001-06-28 2006-04-06 Domantis Limited Compositions and methods for treating inflammatory disorders
CA2455365C (en) 2001-08-03 2014-07-29 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
CA2457636C (en) 2001-08-10 2012-01-03 Aberdeen University Antigen binding domains
JP4213586B2 (ja) 2001-09-13 2009-01-21 株式会社抗体研究所 ラクダ抗体ライブラリーの作製方法
JP2005289809A (ja) 2001-10-24 2005-10-20 Vlaams Interuniversitair Inst Voor Biotechnologie Vzw (Vib Vzw) 突然変異重鎖抗体
ATE430580T1 (de) 2001-10-25 2009-05-15 Genentech Inc Glycoprotein-zusammensetzungen
AU2002361784A1 (en) * 2001-12-20 2003-07-09 Human Genome Sciences, Inc. Antibodies that immunospecifically bind to trail receptors
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
US7745140B2 (en) 2002-01-03 2010-06-29 The Trustees Of The University Of Pennsylvania Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
WO2003084570A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
ES2362419T3 (es) 2002-04-09 2011-07-05 Kyowa Hakko Kirin Co., Ltd. Células con depresión o deleción de la actividad de la proteína que participa en el transporte de gdp-fucosa.
CN1930288B (zh) 2002-04-09 2012-08-08 协和发酵麒麟株式会社 基因组被修饰的细胞
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
CA2488441C (en) 2002-06-03 2015-01-27 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
GB0228210D0 (en) 2002-12-03 2003-01-08 Babraham Inst Single chain antibodies
PT1572744E (pt) 2002-12-16 2010-09-07 Genentech Inc Variantes de imunoglobulina e utilizações destas
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
AU2004279742A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kirin Co., Ltd. Fused protein composition
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
ME01775B (me) 2003-11-05 2011-02-28 Glycart Biotechnology Ag Cd20 antitijela sa povećanim afinitetom vezivanja za fc receptor i efektornom funkcijom
NZ583292A (en) 2003-11-06 2012-03-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
BR122019012028B1 (pt) 2004-04-13 2023-09-26 F. Hoffmann-La Roche Ag Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
ES2653570T3 (es) 2004-05-27 2018-02-07 The Trustees Of The University Of Pennsylvania Células presentadoras de antígeno artificiales novedosas y usos de las mismas
WO2006008548A2 (en) 2004-07-22 2006-01-26 Erasmus University Medical Centre Rotterdam Binding molecules
US7563443B2 (en) 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
TWI380996B (zh) 2004-09-17 2013-01-01 Hoffmann La Roche 抗ｏｘ４０ｌ抗體
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
BRPI0706750A2 (pt) 2006-01-25 2011-04-05 Univ Erasmus Medical Ct geração de anticorpos de cadeia pesada em animais transgênicos
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
US20100166734A1 (en) 2006-12-20 2010-07-01 Edward Dolk Oral delivery of polypeptides
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
SG182192A1 (en) * 2007-06-12 2012-07-30 Ac Immune Sa Humanized antibodies to amyloid beta
CN101970490A (zh) 2007-11-27 2011-02-09 埃博灵克斯股份有限公司 针对异二聚体细胞因子和/或其受体的氨基酸序列以及包括所述氨基酸序列的多肽
PT2235064E (pt) 2008-01-07 2016-03-01 Amgen Inc Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
CN101550416B (zh) * 2008-03-18 2012-01-25 陈志南 人源化单抗Hu-ScFv18的轻、重链可变区基因和其编码多肽及其应用
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
US8754287B2 (en) 2009-12-10 2014-06-17 Regeneron Pharmaceuticals, Inc. Mice that make heavy chain antibodies
TW201206473A (en) 2010-08-03 2012-02-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
JP6219832B2 (ja) 2011-10-17 2017-10-25 マサチューセッツ インスティテュート オブ テクノロジー 細胞内送達
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
WO2013154760A1 (en) 2012-04-11 2013-10-17 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric antigen receptors targeting b-cell maturation antigen
US9365641B2 (en) * 2012-10-01 2016-06-14 The Trustees Of The University Of Pennsylvania Compositions and methods for targeting stromal cells for the treatment of cancer
US9243058B2 (en) * 2012-12-07 2016-01-26 Amgen, Inc. BCMA antigen binding proteins
TW201425336A (zh) 2012-12-07 2014-07-01 Amgen Inc Ｂｃｍａ抗原結合蛋白質
CN104045713B (zh) * 2013-03-13 2019-02-12 江苏诺迈博生物医药科技有限公司 一种抗Blys的单克隆抗体及含有该抗体的药物组合物
EP2970426B1 (en) 2013-03-15 2019-08-28 Michael C. Milone Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
CN103421115B (zh) 2013-09-02 2015-06-03 东南大学 一种cd38纳米抗体及应用
GB201317929D0 (en) 2013-10-10 2013-11-27 Ucl Business Plc Chimeric antigen receptor
US10189908B2 (en) 2014-02-05 2019-01-29 The University Of Chicago Chimeric antigen receptors recognizing cancer-specific TN glycopeptide variants
ES2857226T3 (es) 2014-03-15 2021-09-28 Novartis Ag Receptor de antígeno quimérico regulable
WO2015142675A2 (en) * 2014-03-15 2015-09-24 Novartis Ag Treatment of cancer using chimeric antigen receptor
RU2016141307A (ru) 2014-03-21 2018-04-24 Регенерон Фармасьютикалз, Инк. Отличные от человека животные, которые вырабатывают однодоменные связывающие белки
EP3131927B8 (en) 2014-04-14 2020-12-23 Cellectis Bcma (cd269) specific chimeric antigen receptors for cancer immunotherapy
SI3689899T1 (sl) 2014-04-25 2022-01-31 2Seventy Bio, Inc. MND promotor kimeričnih antigenskih receptorjev
NZ726989A (en) 2014-06-06 2020-08-28 Bluebird Bio Inc Improved t cell compositions
WO2016014565A2 (en) 2014-07-21 2016-01-28 Novartis Ag Treatment of cancer using humanized anti-bcma chimeric antigen receptor
SG10201900455YA (en) 2014-07-24 2019-02-27 Bluebird Bio Inc Bcma chimeric antigen receptors
KR102411972B1 (ko) 2014-08-04 2022-06-23 에프. 호프만-라 로슈 아게 이중특이적 t 세포 활성화 항원 결합 분자
EP3029067A1 (en) 2014-12-01 2016-06-08 Deutsches Krebsforschungszentrum Use of blocking-reagents for reducing unspecific T cell-activation
US20180334490A1 (en) * 2014-12-03 2018-11-22 Qilong H. Wu Methods for b cell preconditioning in car therapy
NZ733025A (en) * 2014-12-12 2022-01-28 2Seventy Bio Inc Bcma chimeric antigen receptors
RU2018105986A (ru) 2015-07-20 2019-08-20 Анджиокрин Биосайенс, Инк. Сконструированные эндотелиальные клетки, экспрессирующие фактор транскрипции ets
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
CN105777911B (zh) 2016-04-12 2019-07-02 上海优卡迪生物医药科技有限公司 抗bcma嵌合抗原受体、编码基因、重组表达载体及其构建方法和应用
CN105837693A (zh) 2016-05-30 2016-08-10 李斯文 一种基于bcma的抗原嵌合受体及其制备方法和应用
CN108395481B (zh) 2017-02-08 2021-02-05 西比曼生物科技（香港）有限公司 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
EP3612275A1 (en) 2017-04-19 2020-02-26 Allogene Therapeutics, Inc. Improved t cell compositions and methods
WO2019000223A1 (en) 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
CN109306014B (zh) 2017-07-27 2022-04-12 上海细胞治疗研究院 一种靶向间皮素的嵌合抗原受体修饰t细胞及其用途
IL318172A (en) 2017-12-29 2025-03-01 Memorial Sloan Kettering Cancer Center Enhanced chimeric antigen receptors and uses thereof
WO2019157496A1 (en) 2018-02-12 2019-08-15 University Of Florida Researchfoundation, Inc. Fviii chimeric antigen receptor tregs for tolerance induction in hemophilia a
TW202122574A (zh) 2019-08-28 2021-06-16 大陸商南京傳奇生物科技有限公司 含有ｎｅｆ的ｔ細胞及其產生方法
JOP20220049A1 (ar) 2019-08-30 2023-01-30 Janssen Biotech Inc مشرعات وتركيبات car t خاصة بمركب نضج الخلايا البائية
EP4077398A4 (en) 2019-12-16 2024-04-10 Legend Biotech Ireland Limited SINGLE DOMAIN ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS TARGETING BCMA AND METHODS OF USE THEREOF
US20210332448A1 (en) 2020-03-09 2021-10-28 Janssen Pharmaceutica Nv Compositions and methods for quantifying integration of recombinant vector nucleic acid
WO2021214692A1 (en) 2020-04-24 2021-10-28 Janssen Biotech, Inc. Neurologic toxicity assessment methods and systems for documenting changes in handwriting
JP2023530238A (ja) 2020-06-08 2023-07-14 ヤンセン バイオテツク，インコーポレーテツド キメラ抗原発現免疫細胞のインビトロ腫瘍殺傷活性を決定するための細胞ベースのアッセイ

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011154453A1 (en) * 2010-06-09 2011-12-15 Genmab A/S Antibodies against human cd38
WO2013123061A1 (en) * 2012-02-13 2013-08-22 Seattle Children's Hospital D/B/A Seattle Children's Research Institute Bispecific chimeric antigen receptors and therapeutic uses thereof
CN104136458A (zh) * 2012-02-22 2014-11-05 宾夕法尼亚大学董事会 在第二代嵌合抗原受体中cd2信号传导结构域的使用
CN104583230A (zh) * 2012-07-13 2015-04-29 宾夕法尼亚大学董事会 通过共同引入双特异性抗体增强car t细胞的活性
WO2014122143A1 (en) * 2013-02-05 2014-08-14 Engmab Ag Method for the selection of antibodies against bcma
WO2014153270A1 (en) * 2013-03-16 2014-09-25 Novartis Ag Treatment of cancer using humanized anti-cd19 chimeric antigen receptor
WO2014165707A2 (en) * 2013-04-03 2014-10-09 Memorial Sloan-Kettering Cancer Center Effective generation of tumor-targeted t-cells derived from pluripotent stem cells

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
MICHAEL KALOS等: "T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia", 《SCI TRANSL MED.》 *
RENIER BRENTJENS等: "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia", 《SCI TRANSL MED.》 *
STEPHAN A. GRUPP等: "Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid", 《N ENGL J MED.》 *
徐云云等: "血液肿瘤治疗中嵌合抗原受体基因修饰T淋巴细胞作用", 《中国实用儿科杂志》 *
徐晓军等: "嵌合抗原受体技术免疫治疗血液系统恶性肿瘤的研究进展", 《中国实验血液学杂志》 *
袁顺宗等: "利用嵌合抗原受体的T细胞(CAＲ-T) 治疗复发和难治B细胞淋巴瘤/白血病的转化医学研究", 《中国实验血液学杂志》 *

Cited By (147)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11535677B2 (en) 2015-08-11 2022-12-27 Legend Biotech Usa Inc. Chimeric antigen receptors targeting BCMA and methods of use thereof
US12351638B2 (en) 2015-08-11 2025-07-08 Legend Biotech Usa Inc. Chimeric antigen receptors targeting BCMA and methods of use thereof
US10934363B2 (en) 2015-08-11 2021-03-02 Legend Biotech Usa Inc. Chimeric antigen receptors based on single domain antibodies and methods of use thereof
US11186647B2 (en) 2015-08-11 2021-11-30 Legend Biotech Usa Inc. Chimeric antigen receptors targeting BCMA and methods of use thereof
WO2018028647A1 (en) * 2015-08-11 2018-02-15 Legend Biotech Usa Inc. Chimeric antigen receptors targeting bcma and methods of use thereof
US10975161B2 (en) 2016-01-12 2021-04-13 Crescendo Biologics Limited Molecules that bind prostate specific membrane antigen (PSMA)
US11746158B2 (en) 2016-01-12 2023-09-05 Crescendo Biologics Limited Therapeutic molecules
US11236174B2 (en) 2016-01-12 2022-02-01 Crescendo Biologics Limited Therapeutic molecules
CN105647946B (zh) * 2016-03-18 2019-09-20 江苏普瑞康生物医药科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
CN105647946A (zh) * 2016-03-18 2016-06-08 苏州康元生物科技有限公司 一种基于FcγRⅢa的嵌合基因及其用途
KR20220110338A (ko) * 2016-04-01 2022-08-05 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
KR20180133252A (ko) * 2016-04-01 2018-12-13 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
JP2019516350A (ja) * 2016-04-01 2019-06-20 カイト ファーマ インコーポレイテッドＫｉｔｅ Ｐｈａ キメラ抗原及びｔ細胞受容体、並びに使用方法
JP7379561B2 (ja) 2016-04-01 2023-11-14 カイト ファーマ インコーポレイテッド キメラ抗原及びｔ細胞受容体、並びに使用方法
CN109328074A (zh) * 2016-04-01 2019-02-12 凯德药业股份有限公司 嵌合抗原和t细胞受体及使用的方法
KR102427334B1 (ko) 2016-04-01 2022-08-03 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
JP2022078179A (ja) * 2016-04-01 2022-05-24 カイト ファーマ インコーポレイテッド キメラ抗原及びｔ細胞受容体、並びに使用方法
JP7034934B2 (ja) 2016-04-01 2022-03-14 カイト ファーマ インコーポレイテッド キメラ抗原及びｔ細胞受容体、並びに使用方法
KR102584280B1 (ko) 2016-04-01 2023-10-04 카이트 파마 인코포레이티드 키메라 항원 및 t 세포 수용체 및 사용 방법
US11505613B2 (en) 2016-04-01 2022-11-22 Kite Pharma, Inc. BCMA binding molecules and methods of use thereof
WO2017191476A1 (en) * 2016-05-06 2017-11-09 Crescendo Biologics Limited Chimeric antigen receptor with single domain antibody
US11866510B2 (en) 2016-05-06 2024-01-09 Crescendo Biologics Limited Chimeric antigen receptor with single domain antibody
US11613572B2 (en) 2016-06-21 2023-03-28 Teneobio, Inc. CD3 binding antibodies
EP3484927A1 (en) * 2016-07-15 2019-05-22 Poseida Therapeutics, Inc. Chimeric antigen receptors (cars) specific for muc1 and methods for their use
JP2019528044A (ja) * 2016-07-15 2019-10-10 ポセイダ セラピューティクス， インコーポレイテッド Ｍｕｃ１に特異的なキメラ抗原受容体（ｃａｒｓ）およびその使用方法
EP3485017A4 (en) * 2016-07-18 2020-03-04 Helix Biopharma Corp. IMMUNE CELLS CAR DIRECTED AGAINST CARCINO-EMBRYONARY ANTIGEN CELL ADHESION MOLECULE 6 FOR CANCER TREATMENT
CN109843325B (zh) * 2016-09-14 2023-10-03 特尼奥生物股份有限公司 Cd3结合抗体
US11421027B2 (en) 2016-09-14 2022-08-23 Teneoone, Inc. CD3 binding antibodies
US11505606B2 (en) 2016-09-14 2022-11-22 Teneobio, Inc. CD3 binding antibodies
CN109843325A (zh) * 2016-09-14 2019-06-04 特尼奥生物股份有限公司 Cd3结合抗体
CN108699163B (zh) * 2016-09-28 2021-11-19 阿思科力(苏州)生物科技有限公司 一种多基因重组嵌合抗原受体分子及其应用
CN108699163A (zh) * 2016-09-28 2018-10-23 阿思科力(苏州)生物科技有限公司 一种多基因重组嵌合抗原受体分子及其应用
WO2018058432A1 (zh) * 2016-09-28 2018-04-05 李华顺 一种多基因重组嵌合抗原受体分子及其应用
CN109843923A (zh) * 2016-10-11 2019-06-04 南京传奇生物科技有限公司 针对ctla-4的单结构域抗体及其变体
CN106701827A (zh) * 2016-12-05 2017-05-24 刘晓明 表达cd19和cd20抗体基因嵌合抗原受体t细胞的转化及扩增培养与保存方法
CN106755109A (zh) * 2016-12-05 2017-05-31 刘晓明 一种表达人cd19和cd20嵌合抗原受体基因的慢病毒载体
CN106755108A (zh) * 2016-12-05 2017-05-31 刘晓明 一种表达cd19和cd20抗体基因嵌合抗原受体的慢病毒载体及其制备方法
EP3895712B1 (en) 2016-12-09 2022-06-22 ONK Therapeutics Limited Engineered natural killer cells and uses thereof
CN106822184A (zh) * 2016-12-15 2017-06-13 梁爱斌 多靶点联合的car‑t细胞制剂与制备方法
JP7589269B2 (ja) 2016-12-21 2024-11-25 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
JP2020505001A (ja) * 2016-12-21 2020-02-20 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
US11434299B2 (en) 2016-12-21 2022-09-06 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
JP2023071684A (ja) * 2016-12-21 2023-05-23 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
JP2025037879A (ja) * 2016-12-21 2025-03-18 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
US12371505B2 (en) 2016-12-21 2025-07-29 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
JP7254699B2 (ja) 2016-12-21 2023-04-10 テネオバイオ， インコーポレイテッド 抗ｂｃｍａ重鎖のみ抗体
CN108276493A (zh) * 2016-12-30 2018-07-13 南京传奇生物科技有限公司 一种新型嵌合抗原受体及其应用
CN108276493B (zh) * 2016-12-30 2023-11-14 南京传奇生物科技有限公司 一种嵌合抗原受体及其应用
CN106749677A (zh) * 2017-01-04 2017-05-31 上海交通大学医学院附属瑞金医院 一种靶向mll白血病的双特异性嵌合抗原受体基因及其应用
US11591398B2 (en) 2017-01-06 2023-02-28 Crescendo Biologics Limited Single domain antibodies to programmed cell death protein 1 (PD-1)
US11814429B2 (en) 2017-01-06 2023-11-14 Crescendo Biologics Limited Single domain antibodies to programmed cell death (PD-1)
CN108728465A (zh) * 2017-04-14 2018-11-02 深圳新诺微环生物科技有限公司 一种表达靶细胞-效应细胞桥接器的微环dna载体及其制备方法和应用
WO2018218876A1 (zh) * 2017-05-27 2018-12-06 上海优卡迪生物医药科技有限公司 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
CN107245500A (zh) * 2017-05-27 2017-10-13 上海优卡迪生物医药科技有限公司 一种基于octs技术的淋系白血病car‑t治疗载体及其构建方法和应用
CN107299110A (zh) * 2017-05-27 2017-10-27 上海优卡迪生物医药科技有限公司 一种基于octs技术的胰腺癌、恶性间皮瘤car‑t治疗载体及其构建方法和应用
CN107299110B (zh) * 2017-05-27 2019-11-22 上海优卡迪生物医药科技有限公司 一种基于octs技术的胰腺癌、恶性间皮瘤car-t治疗载体及其构建方法和应用
CN107245500B (zh) * 2017-05-27 2019-05-17 上海优卡迪生物医药科技有限公司 一种基于octs技术的淋系白血病car-t治疗载体及其构建方法和应用
US11098123B2 (en) 2017-05-27 2021-08-24 Shanghai Unicar-Therapy Bio-Medicine Technology Co., Ltd OCTS technology-based pancreatic cancer and malignant mesothelioma CAR-T therapeutic vector, construction method therefor, and use thereof
CN110945026B (zh) * 2017-06-20 2024-03-19 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
US11427642B2 (en) 2017-06-20 2022-08-30 Teneoone, Inc. Anti-BCMA heavy chain-only antibodies
CN110945026A (zh) * 2017-06-20 2020-03-31 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
US11970540B2 (en) 2017-06-20 2024-04-30 Teneobio, Inc. Anti-BCMA heavy chain-only antibodies
US11401342B2 (en) 2017-07-10 2022-08-02 Crescendo Biologics Limited Therapeutic molecules binding PSMA
CN109232742A (zh) * 2017-07-11 2019-01-18 深圳市第二人民医院 一种嵌合抗原受体及其应用
CN109232742B (zh) * 2017-07-11 2021-10-22 深圳市第二人民医院 一种嵌合抗原受体及其应用
WO2019014891A1 (zh) * 2017-07-20 2019-01-24 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用
CN109996872A (zh) * 2017-07-20 2019-07-09 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用
US12077595B2 (en) 2017-11-13 2024-09-03 Crescendo Biologics Limited Single domain antibodies that bind to CD137
CN114656569B (zh) * 2017-12-28 2024-01-30 南京传奇生物科技有限公司 包含nkg2d结构域的多特异性嵌合受体和其使用方法
CN114656570B (zh) * 2017-12-28 2024-03-01 南京传奇生物科技有限公司 包含nkg2d结构域的多特异性嵌合受体和其使用方法
CN114656569A (zh) * 2017-12-28 2022-06-24 南京传奇生物科技有限公司 包含nkg2d结构域的多特异性嵌合受体和其使用方法
CN114656570A (zh) * 2017-12-28 2022-06-24 南京传奇生物科技有限公司 包含nkg2d结构域的多特异性嵌合受体和其使用方法
CN111836827A (zh) * 2017-12-28 2020-10-27 南京传奇生物科技有限公司 包含nkg2d结构域的多特异性嵌合受体和其使用方法
CN109971715A (zh) * 2017-12-28 2019-07-05 深圳华大生命科学研究院 一种扩增特异性car-t细胞的培养方法
CN109988242A (zh) * 2018-01-02 2019-07-09 武汉波睿达生物科技有限公司 联合嵌合抗原受体、表达载体、慢病毒及t细胞
CN108285486A (zh) * 2018-01-15 2018-07-17 浙江阿思科力生物科技有限公司 以cd20为靶点的特异性抗体、car-nk细胞及其制备和应用
CN108341881B (zh) * 2018-01-31 2020-08-18 深圳市默赛尔生物医学科技发展有限公司 带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN108341881A (zh) * 2018-01-31 2018-07-31 深圳市默赛尔生物医学科技发展有限公司 带安全开关的嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN108314739A (zh) * 2018-02-05 2018-07-24 深圳市默赛尔生物医学科技发展有限公司 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN108314739B (zh) * 2018-02-05 2020-07-14 深圳市默赛尔生物医学科技发展有限公司 多信号嵌合抗原受体及其表达基因、其修饰的nk细胞及应用
CN110129369A (zh) * 2018-02-09 2019-08-16 上海交通大学医学院附属上海儿童医学中心 一种嵌合抗原受体基因工程载体、免疫细胞及其应用
CN110129369B (zh) * 2018-02-09 2023-10-13 上海交通大学医学院附属上海儿童医学中心 一种嵌合抗原受体基因工程载体、免疫细胞及其应用
US11951172B2 (en) 2018-02-16 2024-04-09 Crescendo Biologics Limited Therapeutic molecules that bind to LAG3 and PD1
CN108220247A (zh) * 2018-03-20 2018-06-29 杭州史迪姆生物科技有限公司 一种双car-t细胞及其制备方法和应用
US11498973B2 (en) 2018-04-12 2022-11-15 Cellular Biomedicine Group Hk Limited BCMA-targeted chimeric antigen receptor as well as preparation method therefor and application thereof
CN110372796B (zh) * 2018-04-12 2023-05-02 上海赛比曼生物科技有限公司 靶向bcma的嵌合抗原受体及其制法和应用
CN110372796A (zh) * 2018-04-12 2019-10-25 西比曼生物科技（香港）有限公司 靶向bcma的嵌合抗原受体及其制法和应用
CN110606893B (zh) * 2018-06-15 2022-11-15 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
CN110606893A (zh) * 2018-06-15 2019-12-24 北昊干细胞与再生医学研究院有限公司 一种靶向cd19和cd20双抗原的嵌合性抗原受体t细胞治疗肿瘤的方法
CN109134665A (zh) * 2018-08-24 2019-01-04 深圳普瑞金生物药业有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
WO2020038146A1 (zh) * 2018-08-24 2020-02-27 深圳普瑞金生物药业有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
WO2020038147A1 (zh) * 2018-08-24 2020-02-27 深圳普瑞金生物药业有限公司 抗bcma的单域抗体及其应用
CN109134665B (zh) * 2018-08-24 2021-06-11 上海先博生物科技有限公司 一种基于单域抗体的bcma嵌合抗原受体及应用
US12227581B2 (en) 2018-08-24 2025-02-18 Shenzhen Pregene Biopharma Co., Ltd. Anti-BCMA single domain antibodies and application thereof
CN111542343A (zh) * 2018-08-24 2020-08-14 深圳普瑞金生物药业有限公司 抗bcma的单域抗体及其应用
CN111542343B (zh) * 2018-08-24 2023-08-18 上海先博生物科技有限公司 抗bcma的单域抗体及其应用
TWI841595B (zh) * 2018-09-10 2024-05-11 大陸商南京傳奇生物科技有限公司 針對ｃｄ３３之單域抗體及其構築體
US12275788B2 (en) 2018-09-10 2025-04-15 Legend Biotech Ireland Limited Single-domain antibodies against CD33 and constructs thereof
WO2020061796A1 (en) * 2018-09-26 2020-04-02 Hrain Biotechnology Co., Ltd. Bcma-and-cd19-targeting chimeric antigen receptor and uses thereof
CN109503716B (zh) * 2018-10-08 2021-04-27 浙江生研生物科技有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
CN109503716A (zh) * 2018-10-08 2019-03-22 生研医药科技（武汉）有限公司 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用
CN109504660A (zh) * 2018-11-02 2019-03-22 温州启星生物技术有限公司 一种第四代car-t细胞及其构建方法和应用
CN109504660B (zh) * 2018-11-02 2021-08-06 温州启星生物技术有限公司 一种第四代car-t细胞及其构建方法和应用
WO2020108642A1 (en) * 2018-11-30 2020-06-04 Beijing Meikang Geno-Immune Biotechnology Co., Ltd. Cd19-and cd30-based combined car-t immunotherapy
CN109468283A (zh) * 2018-11-30 2019-03-15 北京美康基免生物科技有限公司 一种基于cd19和bcma的双重嵌合抗原受体基因修饰的免疫细胞及其应用
WO2020125277A1 (zh) * 2018-12-20 2020-06-25 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
CN109485732A (zh) * 2018-12-20 2019-03-19 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
US12281164B2 (en) 2018-12-20 2025-04-22 West China Hospital, Sichuan University Genetically engineered dual-targeting chimeric antigen receptor and use thereof
CN109485732B (zh) * 2018-12-20 2021-09-24 四川大学华西医院 基因工程修饰的双靶点嵌合抗原受体及其用途
CN109652379A (zh) * 2018-12-29 2019-04-19 博生吉医药科技(苏州)有限公司 Cd7嵌合抗原受体修饰的nk-92mi细胞及其应用
CN109485734A (zh) * 2018-12-30 2019-03-19 广州百暨基因科技有限公司 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
CN113330038A (zh) * 2019-01-22 2021-08-31 亘喜生物科技（上海）有限公司 Cd20组合靶向的工程化免疫细胞
CN109734814A (zh) * 2019-02-12 2019-05-10 南京卡提医学科技有限公司 具有免疫受体的工程化t细胞治疗癌症的用途
US12005081B2 (en) 2019-04-30 2024-06-11 Senti Biosciences, Inc. Chimeric receptors and methods of use thereof
CN114040927A (zh) * 2019-05-04 2022-02-11 印希比股份有限公司 结合cd33的多肽及其用途
US11905326B2 (en) 2019-06-14 2024-02-20 Teneobio, Inc. Multispecific heavy chain antibodies binding to CD22 and CD3
CN112739721B (zh) * 2019-09-26 2023-01-31 苏州克睿基因生物科技有限公司 一种单域抗体及包含抗体结构的嵌合抗原受体
CN112739721A (zh) * 2019-09-26 2021-04-30 苏州克睿基因生物科技有限公司 一种单域抗体及包含抗体结构的嵌合抗原受体
CN114829405A (zh) * 2019-12-10 2022-07-29 爱必乐生物公司 抗bcma/抗4-1bb双特异性抗体及其用途
CN111235113A (zh) * 2020-01-21 2020-06-05 南京北恒生物科技有限公司 包含嵌合抗原受体的免疫细胞及其用途
CN111196858B (zh) * 2020-02-05 2021-02-09 武汉科技大学 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
CN111196858A (zh) * 2020-02-05 2020-05-26 武汉科技大学 一种治疗血液肿瘤合并hiv感染的双特异性嵌合抗原受体、基因、构建方法及其应用
CN111574629B (zh) * 2020-06-01 2021-07-20 宁夏医科大学 一种抗cd20的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
CN111574629A (zh) * 2020-06-01 2020-08-25 宁夏医科大学 一种抗cd20的纳米抗体、编码基因、重组纳米抗体、重组载体、重组菌株和应用
WO2022161409A1 (zh) * 2021-01-29 2022-08-04 武汉思安医疗技术有限公司 双特异性cs1-bcma car-t细胞及其应用
WO2022199590A1 (zh) * 2021-03-22 2022-09-29 浙江纳米抗体技术中心有限公司 一种靶向bcma的纳米抗体及其应用
WO2023044991A1 (zh) * 2021-09-24 2023-03-30 四川大学 一种特异性靶向肿瘤EpCAM抗原的抗体及应用
CN114195898A (zh) * 2021-12-13 2022-03-18 南京凯地医疗技术有限公司 人源化抗cd33的单域抗体及其构建体制备方法和应用
CN114685664A (zh) * 2022-04-12 2022-07-01 内蒙古农业大学 抗人b淋巴细胞表面抗原cd20的单域抗体及其应用
CN114685664B (zh) * 2022-04-12 2023-10-20 内蒙古农业大学 抗人b淋巴细胞表面抗原cd20的单域抗体及其应用
WO2024041650A1 (en) * 2022-08-25 2024-02-29 Nanjing Legend Biotech Co., Ltd. Chimeric antigen receptors targeting interleukin 13 receptor subunit alpha 2 and methods of use thereof
WO2024051096A1 (zh) * 2022-09-05 2024-03-14 上海百英生物科技股份有限公司 一种抗cd40纳米抗体及其制备方法与应用
CN117069844B (zh) * 2022-12-06 2024-02-09 成都赛恩吉诺生物科技有限公司 包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
CN117069844A (zh) * 2022-12-06 2023-11-17 成都赛恩吉诺生物科技有限公司 包含特定等电点的抗人bcma纳米抗体的双特异性抗体及应用
CN117164712A (zh) * 2023-02-22 2023-12-05 成都优赛诺生物科技有限公司 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
CN116199781B (zh) * 2023-02-22 2025-07-18 成都优赛诺生物科技有限公司 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
CN116199781A (zh) * 2023-02-22 2023-06-02 成都优赛诺生物科技有限公司 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
CN117164712B (zh) * 2023-02-22 2024-05-24 成都优赛诺生物科技有限公司 一种靶向cd22的单域抗体、嵌合抗原受体及其应用
US12311022B2 (en) 2023-03-31 2025-05-27 AbelZeta Inc. Bispecific chimeric antigen receptors targeting CD20 and BCMA
US12458667B2 (en) 2023-03-31 2025-11-04 AbelZeta Inc. Bispecific chimeric antigen receptors targeting CD20 and BCMA
WO2024240248A1 (zh) * 2023-05-24 2024-11-28 茂行制药(苏州)有限公司 用于靶向b7h3的同种异体嵌合抗原受体t细胞的给药的方法和组合物
CN116949099A (zh) * 2023-07-12 2023-10-27 山东大学第二医院 一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用
CN116949099B (zh) * 2023-07-12 2024-04-02 山东大学第二医院 一种靶向cd38和cs1抗原的并联嵌合抗原受体t细胞及其制备方法和应用
CN117024594B (zh) * 2023-09-21 2025-02-28 武汉波睿达生物科技有限公司 一种抗cd20的纳米抗体及其应用
CN117024594A (zh) * 2023-09-21 2023-11-10 武汉波睿达生物科技有限公司 一种抗cd20的纳米抗体及其应用
CN120173114A (zh) * 2025-03-24 2025-06-20 广州泽朗生物医药科技有限公司 Cart细胞及其在制备抗癌症药物中的应用
CN120173114B (zh) * 2025-03-24 2025-09-26 广州泽朗生物医药科技有限公司 Cart细胞及其在制备抗癌症药物中的应用

Also Published As

Publication number Publication date
US12351638B2 (en) 2025-07-08
PH12019500193A1 (en) 2019-07-29
MX2024010240A (es) 2024-09-11
HRP20231542T1 (hr) 2024-03-15
AU2021200453C1 (en) 2023-11-16
CA3019453A1 (en) 2018-02-15
MX2019001294A (es) 2019-04-25
FI3896091T3 (fi) 2023-12-04
AU2020200151B2 (en) 2022-03-17
HRP20241057T1 (hr) 2024-11-08
KR20180035918A (ko) 2018-04-06
MY188362A (en) 2021-12-03
US20240409654A1 (en) 2024-12-12
DK3896091T5 (da) 2024-08-05
EP4282877A3 (en) 2024-02-21
CN113234173B (zh) 2022-03-11
EA201990208A1 (ru) 2019-07-31
IL264607A (en) 2019-02-28
JP2024032975A (ja) 2024-03-12
US11535677B2 (en) 2022-12-27
JP2025028239A (ja) 2025-02-28
EP3334765A1 (en) 2018-06-20
AU2021200453B2 (en) 2023-03-30
SA518390904B1 (ar) 2023-02-22
EP4282877A2 (en) 2023-11-29
EP3896091B1 (en) 2023-09-27
CA3019453C (en) 2023-04-04
NL301301I2 (nl) 2025-04-09
EP3475307A1 (en) 2019-05-01
EP4282878A3 (en) 2024-03-06
NZ791176A (en) 2025-09-26
CO2018001405A2 (es) 2018-11-22
RS64925B1 (sr) 2023-12-29
RS65866B1 (sr) 2024-09-30
CN113185615A (zh) 2021-07-30
HUE064534T2 (hu) 2024-03-28
CN113234174B (zh) 2024-01-09
AU2017311089A1 (en) 2019-02-21
KR20240017408A (ko) 2024-02-07
EP4063397B1 (en) 2024-06-19
MY199874A (en) 2023-11-27
FR24C1050I1 (fr) 2025-01-17
EP4282878A2 (en) 2023-11-29
FI4063397T3 (fi) 2024-08-09
EP4424376A3 (en) 2024-12-04
EP4424376A2 (en) 2024-09-04
KR20240173368A (ko) 2024-12-11
CN109311999A (zh) 2019-02-05
ES2984851T3 (es) 2024-10-31
US20210163615A1 (en) 2021-06-03
WO2018028647A1 (en) 2018-02-15
JP2023024810A (ja) 2023-02-16
SG10201913485QA (en) 2020-02-27
CN113234174A (zh) 2021-08-10
IL294683A (en) 2022-09-01
JP2022183283A (ja) 2022-12-08
ZA201800703B (en) 2018-12-19
US11186647B2 (en) 2021-11-30
KR20250107971A (ko) 2025-07-14
NO2024054I1 (no) 2024-12-10
ES2966992T3 (es) 2024-04-25
KR102512934B1 (ko) 2023-03-23
JP2021094037A (ja) 2021-06-24
AU2016305075B2 (en) 2019-10-10
FIC20240042I1 (fi) 2024-12-11
AU2022204180A1 (en) 2022-07-07
AU2020200151C1 (en) 2022-09-08
BR112019002687A2 (pt) 2019-05-14
CA2994579C (en) 2023-07-11
CA3189388A1 (en) 2018-02-15
SA519401072B1 (ar) 2024-02-01
UA125818C2 (uk) 2022-06-15
HUS2400044I1 (hu) 2025-01-28
PH12018500295A1 (en) 2021-05-10
FR24C1050I2 (fr) 2025-12-05
BR112018002844A2 (pt) 2019-04-30
NZ778787A (en) 2025-05-02
SI4063397T1 (sl) 2024-10-30
AU2020200151A1 (en) 2020-01-30
EP3475307A4 (en) 2020-08-19
IL257297A (en) 2018-03-29
CL2019000326A1 (es) 2019-10-04
JP7696731B2 (ja) 2025-06-23
SG11201900635QA (en) 2019-02-27
KR20240014108A (ko) 2024-01-31
JP2021087455A (ja) 2021-06-10
MY192392A (en) 2022-08-18
CL2018000378A1 (es) 2018-08-17
NZ750366A (en) 2022-10-28
EP4063397A1 (en) 2022-09-28
EP3896091A1 (en) 2021-10-20
KR20230052294A (ko) 2023-04-19
SI3896091T1 (sl) 2024-03-29
SMT202400311T1 (it) 2024-11-15
PL4063397T3 (pl) 2024-11-18
CL2021001686A1 (es) 2022-01-28
CN105384825B (zh) 2018-06-01
CL2021001706A1 (es) 2022-01-28
JP2018525033A (ja) 2018-09-06
US10934363B2 (en) 2021-03-02
CN117756941A (zh) 2024-03-26
EP3334765A4 (en) 2019-05-08
US20220127371A1 (en) 2022-04-28
MX2018001739A (es) 2018-08-15
US20210261675A1 (en) 2021-08-26
LT3896091T (lt) 2023-12-27
PT4063397T (pt) 2024-07-29
CO2019000946A2 (es) 2019-02-08
CR20180153A (es) 2018-08-09
HUE067869T2 (hu) 2024-11-28
EA201890302A1 (ru) 2018-10-31
PT3896091T (pt) 2023-11-29
DK3896091T3 (da) 2023-12-11
JP6851461B2 (ja) 2021-03-31
LTPA2024535I1 (zh) 2024-12-27
LT4063397T (lt) 2024-09-25
CN113185616A (zh) 2021-07-30
MX2022015823A (es) 2023-01-24
AU2017311089B2 (en) 2020-11-19
CN109153731A (zh) 2019-01-04
JP7168173B2 (ja) 2022-11-09
DK4063397T3 (da) 2024-07-22
UA126441C2 (uk) 2022-10-05
PL3896091T3 (pl) 2024-04-29
IL257297B (en) 2022-08-01
CR20210042A (es) 2021-02-26
CR20190050A (es) 2019-06-11
AU2021200453A1 (en) 2021-02-25
CN109153731B (zh) 2021-04-02
US20180230225A1 (en) 2018-08-16
US20200078399A1 (en) 2020-03-12
CA2994579A1 (en) 2017-02-16
JP6859347B2 (ja) 2021-04-14
JP2019527557A (ja) 2019-10-03
CN118085090A (zh) 2024-05-28
WO2017025038A1 (en) 2017-02-16
AU2016305075A1 (en) 2018-03-08
SMT202300425T1 (it) 2024-01-10
KR20190065999A (ko) 2019-06-12
CN113185616B (zh) 2024-03-01
PH12018500295B1 (en) 2023-08-11
ZA201807836B (en) 2019-08-28
CR20210225A (es) 2021-06-24
JP2025159117A (ja) 2025-10-17
MX2024010239A (es) 2024-09-06
CN113234173A (zh) 2021-08-10

Similar Documents

Publication Publication Date Title
CN105384825B (zh) 一种基于单域抗体的双特异性嵌合抗原受体及其应用
JP7237287B2 (ja) 単一ドメイン抗体に基づくｂｃｍａキメラ抗原受容体及びその使用
JP6994456B2 (ja) 抗メソテリン完全ヒト抗体およびメソテリンを標的とする免疫エフェクター細胞
CN105331586B (zh) 一种包含高效杀伤启动机制的肿瘤精准t细胞及其用途
US20190321404A1 (en) Novel chimeric antigen receptor and use thereof
EP3715373A1 (en) Novel scfv amino acid sequence, chimeric antigen receptor comprising same and application thereof
WO2019094482A9 (en) Chimeric antigen receptors targeting tumor antigens
WO2017020812A1 (zh) 抗磷脂酰肌醇蛋白多糖-3的抗体及其应用
CN106554414A (zh) 抗cd19全人抗体以及靶向cd19的免疫效应细胞
WO2014138314A1 (en) Oncolytic virus
CN111909271B (zh) 一种基于单域抗体的bcma嵌合抗原受体及其应用
CN105194661A (zh) 时空可调性抑制病理性靶细胞的系统
CN115838439B (zh) 嵌合转换受体基因修饰的nk细胞制备方法及应用
CN115850476B (zh) 一种cll1抗体及其应用
CN104788567A (zh) 一种靶向鼠T淋巴细胞CD3和人肿瘤抗原EpCAM的双特异性抗体制备方法及应用
US20240016841A1 (en) Cells comprising t cell-antigen couplers and uses thereof
CN104829725A (zh) 一种双特异性抗体cd133×cd3的构建及应用
CN112500487A (zh) 一种抗cd123单克隆抗体及其应用
CN114763387B (zh) 一种基于结构优化蛋白活性的三特异性抗体制备方法
CN112521505B (zh) 抗cd123抗体及其应用
CN119677781A (zh) 靶向cldn18.2的嵌合抗原t细胞受体及其应用
CN116554328B (zh) 一种靶向trbv12的单链抗体、car、car-nk细胞及应用
Xu et al. Universal Dual-Target CAR-γδT Cells Targeting B7-H3 and IL13Rα2 for Glioblastoma Therapy
Renner et al. Enhanced solid tumor cell targeting by a neoepitope-encoding oncolytic measles virus combined with CAR therapy
Wang et al. Nanobody Armed T Cells Endow CAR-T Cells the Ability to Against Lymphoma Cells

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant